documents incorporated reference portions abbvie inc proxy statement incorporated reference part iii definitive proxy statement filed march abbvie inc year ended december table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item mine safety disclosures information executive officers part ii item market registrants common equity related stockholder matters issuer purchases equity securities item reserved item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information item c disclosure regarding foreign jurisdictions prevent inspections part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accounting fees services part iv item exhibits financial statement schedules item summary signatures part item business overview abbvie company refer abbvie inc abbvie inc consolidated subsidiaries context requires abbvie global diversified researchbased biopharmaceutical company positioned success comprehensive product portfolio leadership positions across immunology oncology aesthetics neuroscience eye care abbvie uses expertise dedicated people unique approach innovation develop market advanced therapies address worlds complex serious diseases abbvie incorporated delaware april january abbvie became independent publiclytraded company result distribution abbott laboratories abbott outstanding common stock abbvie abbott 's shareholders segments abbvie operates single global business segment dedicated research development manufacturing commercialization sale innovative medicines therapies operating structure enables chief executive officer chief operating decision maker codm allocate resources assess business performance global basis order achieve established longterm strategic goals consistent structure global research development supply chain organization responsible discovery development manufacturing supply products commercial efforts coordinate marketing sales distribution products organized geographic region therapeutic area activities supported global corporate administrative staff determination single business segment consistent consolidated financial information regularly reviewed codm purposes assessing performance allocating resources planning forecasting future periods see note segment geographic area information consolidated financial statements included item financial statements supplementary data sales information related abbvie 's key products geographies included item management 's discussion analysis financial condition results operations products abbvie 's portfolio products includes broad line therapies address world 's complex serious diseases immunology products abbvie maintains extensive immunology portfolio across rheumatology dermatology gastroenterology abbvie 's immunology products address unmet needs patients autoimmune diseases products humira humira adalimumab biologic therapy administered subcutaneous injection approved treat following autoimmune diseases united states canada mexico collectively north america european union condition principal markets rheumatoid arthritis moderate severe north america european union psoriatic arthritis north america european union ankylosing spondylitis north america european union adult crohn 's disease moderate severe north america european union plaque psoriasis moderate severe chronic north america european union juvenile idiopathic arthritis moderate severe polyarticular north america european union ulcerative colitis moderate severe north america european union axial spondyloarthropathy european union pediatric crohn 's disease moderate severe north america european union hidradenitis suppurativa moderate severe north america european union pediatric enthesitisrelated arthritis european union noninfectious intermediate posterior panuveitis north america european union pediatric ulcerative colitis moderate severe us canada european union pediatric uveitis north america european union form khumira also approved japan treatment intestinal behet 's disease pyoderma gangrenosum humira sold numerous markets worldwide including japan china brazil australia accounted approximately abbvie 's total net revenues skyrizi skyrizi risankizumab interleukin il inhibitor selectively blocks il binding p subunit biologic therapy approved treat following autoimmune diseases north america european union japan condition principal markets plaque psoriasis moderate severe north america european union japan psoriatic arthritis us european union adult crohn 's disease moderate severe us canada european union skyrizi also approved japan treatment plaque psoriasis psoriatic arthritis erythrodermic psoriasis patients inadequate response conventional therapies induction maintenance moderately severely active crohn 's disease skyrizi approved multiple countries globally including united states canada european union treatment moderate severe plaque psoriasis adults candidates systemic therapy phototherapy psoriatic disease psoriasis psoriatic arthritis skyrizi administered quarterly subcutaneous injection following two induction doses administered crohns disease skyrizi given three induction doses via iv infusion followed subcutaneous injection via onbody injector every eight weeks rinvoq rinvoq upadacitinib oral oncedaily selective reversible jak inhibitor approved treat following inflammatory diseases north america european union japan condition principal markets rheumatoid arthritis moderate severe north america european union japan psoriatic arthritis us canada european union japan ankylosing spondylitis us european union atopic dermatitis moderate severe us canada european union japan axial spondyloarthropathy us european union ulcerative colitis us european union united states rinvoq indicated treatment moderate severe active rheumatoid arthritis active psoriatic arthritis moderately severely active ulcerative colitis active ankylosing spondylitis active nonradiographic axial spondyloarthritis adult patients inadequate response intolerance one tnf blockers also indicated treatment moderate severe atopic dermatitis adults children years age older whose disease adequately controlled systemic drug products including biologics use therapies inadvisable european union rinvoq indicated treatment moderate severe rheumatoid arthritis adults active psoriatic arthritis adults inadequate response intolerance diseasemodifying antirheumatic medicines dmards active axial spondyloarthritis adults also indicated treatment moderate severe atopic dermatitis adults children years age older moderately severely active ulcerative colitis adults oncology products abbvies oncology products target complex difficulttotreat cancers products imbruvica imbruvica ibrutinib oral oncedaily therapy inhibits protein called bruton 's tyrosine kinase imbruvica one first medicines receive united states food drug administration fda approval granted breakthrough therapy designation one therapies receive four separate designations imbruvica currently approved treatment adult patients blood cancers chronic lymphocytic leukemia cll well certain forms nonhodgkin lymphoma imbruvica approved adult pediatric patients one year older chronic graft versus host disease failure one lines systemic therapy venclextavenclyxto venclexta venetoclax bcell lymphoma bcl inhibitor used treat hematological malignancies venclexta approved fda adults cll small lymphocytic lymphoma addition venclexta approved combination azacitidine decitabine lowdose cytarabine treat adults newlydiagnosed acute myeloid leukemia years age older medical conditions prevent use standard chemotherapy aesthetics products abbvies aesthetics portfolio consists facial injectables plastics regenerative medicine body contouring skincare products hold marketleading positions us key markets around world products botox cosmetic botox cosmetic acetylcholine release inhibitor neuromuscular blocking agent indicated treatment three areas temporary improvement appearance moderate severe glabellar lines frown lines eyebrows moderate severe crow 's feet moderate severe forehead lines adults received initial fda approval botox cosmetic approved use major markets around world juvederm collection fillers juvederm collection fillers portfolio hyaluronic acidbased dermal fillers variety approved indications us major markets around world augment treat volume loss cheeks chin lips lower face aesthetics aesthetics products include limited alloderm regenerative dermal tissue coolsculpting body contouring technology natrelle breast implants skinmedica skincare line latisse eyelash solution diamondglow dermabrasion technology neuroscience products abbvies neuroscience products address difficulttotreat neurologic diseases products botox therapeutic botox therapeutic onabotulinumtoxina injection acetylcholine release inhibitor neuromuscular blocking agent injected muscle tissue united states approved treat numerous indications including chronic migraine overactive bladder adults inadequate response anticholinergic medication urinary incontinence due detrusor overactivity associated neurologic condition adults inadequate response anticholinergic medication addition botox therapeutic approved treat spasticity patients two years age older cervical dystonia adults well conditions botox marketed countries around world licenses vary botox therapeutic marketed gsk japan vraylar vraylar cariprazine dopamine dpreferring dd receptor partial agonist hta receptor partial agonist vraylar indicated acute maintenance treatment schizophrenia adults acute treatment manic mixed episodes associated bipolar disorder adults acute treatment depressive episodes associated bipolar disorder adults adjunctive treatment major depressive disorder duopa duodopa carbidopa levodopa abbvie 's levodopacarbidopa intestinal gel treatment advanced parkinson 's disease marketed duopa united states duodopa outside united states ubrelvy ubrelvy ubrogepant calcitonin generelated peptide receptor antagonist indicated acute treatment migraine without aura adults ubrelvy commercialized united states israel saudi arabia united arab emirates approved canada qulipta qulipta atogepant calcitonin generelated peptide receptor antagonist indicated preventive treatment episodic migraine adults qulipta commercialized united states recently approved use canada eye care products abbvies eye care products address unmet needs new approaches help preserve protect patients vision products lumiganganfort lumigan bimatoprost ophthalmic solution daily topical prostaglandin analog indicated reduction elevated intraocular pressure iop patients open angle glaucoma oag ocular hypertension oht ganfort daily topical fixed combination bimatoprost timolol reduction iop adult patients oag oht lumigan sold united states numerous markets around world ganfort approved european union markets south america middle east asia alphagancombigan alphagan brimonidine tartrate ophthalmic solution alphaadrenergic receptor agonist indicated reduction elevated iop patients openangle glaucoma ocular hypertension combigan brimonidine tartratetimolol maleate ophthalmic solution approved reducing elevated iop patients glaucoma require additional adjunctive ioplowering therapy alphagan combigan available sale united states numerous markets around world form krestasis restasis calcineurin inhibitor immunosuppressant indicated increase tear production patients whose tear production presumed suppressed due ocular inflammation associated keratoconjunctivitis sicca restasis approved united states number markets south america middle east asia eye care eye care products include ozurdex refreshoptive xen durysta key products abbvies key products include among things treatments patients hepatitis c virus hcv metabolic hormone products target number conditions including exocrine pancreatic insufficiency hypothyroidism well endocrinology products palliative treatment advanced prostate cancer treatment endometriosis central precocious puberty preoperative treatment patients anemia caused uterine fibroids products mavyretmaviret mavyret glecaprevirpibrentasvir approved united states european union maviret treatment adult pediatric patients years older weighing least kilograms chronic hcv genotype infection without cirrhosis compensated cirrhosis childpugh also indicated treatment adult pediatric patients years older weighing least kilograms hcv genotype infection previously treated regimen containing hcv nsa inhibitor nsa protease inhibitor week pangenotypic treatment patients without cirrhosis following expedition study also patients compensated cirrhosis new treatment creon creon pancrelipase pancreatic enzyme therapy exocrine pancreatic insufficiency condition occurs patients cystic fibrosis chronic pancreatitis several conditions lupron lupron leuprolide acetate also marketed lucrin lupron depot product palliative treatment advanced prostate cancer treatment endometriosis central precocious puberty preoperative treatment patients anemia caused uterine fibroids lupron approved daily subcutaneous injection onemonth threemonth fourmonth sixmonth intramuscular injection linzessconstella linzess linaclotide oncedaily guanylate cyclasec agonist used adults treat irritable bowel syndrome constipation ibsc chronic idiopathic constipation product marketed linzess united states constella outside united states synthroid synthroid levothyroxine sodium tablets usp used treatment hypothyroidism abbvie rights sell creon synthroid united states marketing sales distribution capabilities abbvie utilizes combination dedicated commercial resources regional commercial resources distributorships market sell distribute products worldwide abbvie directs primary marketing efforts toward securing prescription recommendation brand products physicians external experts health care providers managed care providers example health maintenance organizations pharmacy benefit managers hospitals state federal government agencies example state medicaid programs united states department veterans affairs united states department defense also important customers abbvie also markets directly consumers although united states many company 's products must sold pursuant prescription outside united states abbvie focuses promotional market access efforts external experts payers physicians health systems abbvie also provides patient support programs closely related products abbvie 's products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers abbvieowned distribution centers public warehouses certain products including aesthetic products devices also sold directly physicians licensed healthcare providers although abbvie 's business significant seasonality abbvie 's product revenues may affected end customer retail buying patterns fluctuations wholesaler inventory levels factors united states abbvie distributes pharmaceutical products principally independent wholesale distributors sales directly retailers pharmacies patients customers three wholesale distributors mckesson corporation cardinal health inc amerisourcebergen corporation accounted substantially abbvie 's pharmaceutical product sales united states individual wholesaler accounted greater abbvie 's gross revenues united states outside united states abbvie sells products primarily wholesalers distributors depending market works largely centralized national payers system agree reimbursement terms certain products comarketed copromoted companies abbvie single customer customer lost would material adverse effect company 's business material portion abbvie 's business subject renegotiation profits termination contracts election government orders generally filled current basis order backlog material abbvie 's business competition markets abbvie 's products highly competitive abbvie competes researchbased pharmaceuticals biotechnology companies discover manufacture market sell proprietary pharmaceutical products therapies biologics example abbvie 's immunology products compete antitnf products jak inhibitors competitive products intended treat number disease states abbvie 's oncology products compete btk inhibitors addition past years number companies started develop successfully developed andor currently marketing products positioned competitors botox search technological innovations pharmaceutical products significant aspect competition introduction new products competitors changes medical practices procedures result product obsolescence price also competitive factor addition substitution generic biosimilar pharmaceutical products branded pharmaceutical products creates competitive pressures abbvie 's products patent protection new products treatments brought market abbvies competitors could cause revenues abbvies products decrease due price reductions sales volume decreases biosimilars competition abbvies biologic products affected approval followon biologics also known biosimilars biologics added major therapeutic options treatment many diseases including therapies unavailable inadequate cost developing producing biologic therapies typically dramatically higher small molecule medications many biologic medications used ongoing treatment chronic diseases rheumatoid arthritis inflammatory bowel disease treatment previously untreatable cancer significant investments biologics infrastructure manufacturing necessary produce biologic products humira facing direct biosimilar competition europe united states countries abbvie continue face competitive pressure biologics orally administered products united states fda regulates biologics federal food drug cosmetic act ffdca public health service act phsa regulations implementing statutes enactment federal health care reform legislation march provided pathway approval biosimilars phsa approval process science behind biosimilars complex approval fda dependent upon many factors including showing biosimilar highly similar original product clinically meaningful differences original product terms safety purity potency types data could ordinarily required application show similarity may include analytical data bioequivalence studies studies demonstrate chemical similarity animal studies including toxicity studies clinical studies furthermore law provides biosimilar product determined interchangeable considered fda substitutable original biologic product without intervention health care provider prescribed original biologic product prove biosimilar product interchangeable applicant must demonstrate product expected produce clinical results original biologic product given patient product administered patient safety risks potential diminished efficacy alternating switching use interchangeable biosimilar biologic product original biologic product greater risk using original biologic product without switching law continues interpreted implemented fda result full ultimate impact implementation meaning remains subject uncertainty intellectual property protection regulatory exclusivity generally upon approval products may entitled certain kinds exclusivity applicable intellectual property regulatory regimes abbvies intellectual property materially valuable company abbvie seeks patent protection available significant markets andor countries product development united states expiration date patents years filing date given patents relating pharmaceutical products often obtained early development process given amount time needed complete clinical trials development activities required regulatory approval length time product launch patent expiration significantly less years drug price competition patent term restoration act commonly known hatchwaxman act permits patent holder seek patent extension commonly called patent term restoration patents products processes making product regulated ffdca length patent extension roughly based percent period time filing investigational new drug application nda form kcompound submission nda compound plus percent time period nda submission regulatory approval extension however exceed five years patent term remaining regulatory approval exceed years biological products licensed phsa similarly eligible terms patent restoration pharmaceutical products may entitled forms legal regulatory exclusivity upon approval scope length requirements exclusivities vary united states jurisdictions united states fda approves conventional drug product contains active ingredient previously approved product typically entitled five years nonpatent regulatory exclusivity specific conditions use approved individual products may also entitled three years exclusivity approval based fdas reliance new clinical studies essential approval submitted nda applicant nda applicant studies product use children fda may grant pediatric exclusivity extends days existing exclusivities patent regulatory related product products either used treat conditions afflict relatively small population reasonable expectation research development costs recovered fda may designate pharmaceutical orphan drug grant seven years exclusivity types regulatory exclusivity may also available generating new antibiotic incentives gain exclusivity provide new antibiotic new antifungal drugs additional five years exclusivity added certain exclusivities already provided law applicable laws regulations dictate scope exclusivity product particular characteristics product entitled upon approval particular country certain instances regulatory exclusivity may offer protection patent protection longer available period time excess patent protection possible estimate product development total period scope exclusivity may become entitled regulatory approval obtained sometimes even later however given length time required complete clinical development pharmaceutical product periods exclusivity might achieved individual case would generally expected exceed minimum three years maximum years estimates consider factors difficulty recreating manufacturing process particular product proprietary knowledge may delay introduction generic followon product expiration applicable patent regulatory exclusivity periods biologics may entitled exclusivity biologics price competition innovation act passed march title vii patient protection affordable care act law provides pathway approval biosimilars following expiration years regulatory exclusivity innovator biologic potential additional dayextension term conducting pediatric studies biologics also eligible orphan drug exclusivity discussed law also includes extensive process innovator biologic biosimilar manufacturer litigate patent infringement validity enforceability european union also created pathway approval biosimilars published guidelines approval certain biosimilar products complex nature biologics biosimilar products led close regulatory scrutiny followon biosimilar products reduce effect biosimilars sales innovator biologic compared sales erosion caused generic versions small molecule pharmaceutical products abbvie owns licensed rights substantial number patents patent applications abbvie licenses owns patent portfolio thousands patent families includes united states patent applications andor issued patents may also contain nonunited states counterparts patents applications patents applications including various patents expire period early aggregate believed material importance operation abbvies business however abbvie believes single patent license trademark related group patents licenses trademarks except related adalimumab sold trademark humira material relation companys business whole abbvie entered settlement license agreements several adalimumab biosimilar manufacturers agreements licenses united states begin licenses europe began addition following patents licenses trademarks significant related ibrutinib sold trademark imbruvica related risankizumab sold trademark skyrizi related upadacitinib sold trademark rinvoq united states composition matter patent covering ibrutinib expected expire pediatric regulatory exclusivity extending may however generic entry ibrutinib product expected prior march united states composition matter patent covering risankizumab expected expire united states composition matter patent covering upadacitinib expected expire abbvie may rely circumstances trade secrets protect technology abbvie seeks protect technology product candidates part confidentiality agreements employees consultants advisors contractors collaborators agreements may breached abbvie may adequate remedies breach addition abbvies trade secrets may otherwise become known independently discovered competitors extent abbvies employees consultants advisors contractors collaborators use intellectual property owned others work company disputes may arise rights related resulting knowhow inventions licensing acquisitions arrangements addition independent efforts develop market products abbvie enters arrangements acquisitions optiontoacquire agreements licensing arrangements optiontolicense arrangements strategic alliances copromotion arrangements codevelopment comarketing agreements joint ventures acquisitions optiontoacquire agreements typically include among terms conditions nonrefundable purchase price payments option fees option exercise payments milestones earnouts customary terms obligations licensing arrangements typically include among terms conditions nonrefundable upfront license fees option fees option exercise payments milestone payments royalty andor profit sharing obligations see note licensing acquisitions arrangementsother licensing acquisitions activity consolidated financial statements included item financial statements supplementary data third party agreements abbvie agreements third parties process development product distribution analytical services manufacturing certain products abbvie procures certain products services limited number suppliers cases single supply source addition abbvie agreements third parties active pharmaceutical ingredient product manufacturing formulation development services fill finish packaging services transportation distribution logistics services certain products abbvie believe manufacturingrelated agreements material abbvie 's business substantially dependent individual agreement cases abbvie maintains alternate supply relationships utilize without undue disruption manufacturing processes third party fails perform contractual obligations abbvie seeks maintain sufficient inventory product minimize impact supply disruption abbvie also party certain collaborations arrangements discussed note licensing acquisitions arrangementsother licensing acquisitions activity consolidated financial statements included item financial statements supplementary data sources availability raw materials abbvie purchases ordinary course business raw materials supplies essential operations numerous suppliers around world addition certain medical devices components necessary manufacture abbvie products provided unaffiliated third party suppliers despite disruption global supply chain caused covid abbvie continued supply patients material supply impact except previously disclosed supply issues impacting lupron given general increased global volatility due pandemic abbvie monitoring taking actions mitigate potential supply shortages may impact fulfillment product demand research development activities abbvie makes significant investment research development numerous compounds complementary devices clinical development including potential treatments complex lifethreatening diseases abbvie 's ability discover develop new compounds enhanced company 's use integrated discovery development project teams include chemists biologists physicians pharmacologists work compounds team abbvie also partners third parties biotechnology companies pharmaceutical companies academic institutions identify prioritize promising new treatments complement enhance abbvies existing portfolio abbvie also supplements research development efforts acquisitions research development process generally begins discovery research focuses identification molecule desired effect given disease preclinical testing identified compound proves successful compound moves clinical development generally includes following phases phase involves first human tests small number healthy volunteers patients assess safety tolerability doses later phases phase tests different doses drug disease state order assess efficacy phase tests drug demonstrates favorable results earlier phases significantly larger patient population demonstrate efficacy safety order meet requirements enable global approval form kpreclinical data clinical trials development phases provide data required prepare submit nda biological license application bla submission regulatory approval fda similar government agencies outside united states specific requirements eg scope clinical trials obtaining regulatory approval vary across different countries geographic regions research development process discovery new drug launch typically takes years even longer research development new pharmaceutical products significant amount inherent uncertainty guarantee molecule receive regulatory approval required launch new drug indication addition development new products delivery devices new formulations research development projects also may include phase trials sometimes called postmarketing studies projects clinical trials designed conducted collect additional data regarding among parameters benefits risks approved drug regulationdiscovery clinical development united states securing approval market new pharmaceutical product united states requires substantial effort financial resources takes several years complete applicant must complete preclinical tests submit protocols fda commencing clinical trials clinical trials intended establish safety efficacy pharmaceutical product typically conducted sequential phases although phases may overlap combined required clinical testing successful results submitted fda form nda bla requesting approval market product one indications fda reviews nda bla determine whether product safe effective intended use whether manufacturing compliant current good manufacturing practices cgmp compliance regulatory requirements assured periodic announced unannounced inspections fda regulatory authorities inspections associated clinical development may include sponsor investigator sites laboratories hospitals manufacturing facilities abbvie 's subcontractors thirdparty manufacturers failure comply applicable regulatory requirements result enforcement action fda including rejection nda bla even nda bla receives approval applicant must comply postapproval requirements example holders approval must report adverse reactions provide updated safety efficacy information comply requirements concerning advertising promotional materials activities also quality control manufacturing procedures must continue conform cgmp approval certain changes manufacturing procedures finished product must submitted approved fda prior implementation fda periodically inspects manufacturing facilities assess compliance cgmp imposes extensive procedural record keeping requirements addition condition approval fda may require postmarketing testing surveillance assess monitor product 's safety efficacy commercialization may require additional clinical trials patient registries observational data additional work chemistry manufacturing controls postapproval regulatory obligations cost complying obligations could expand future fda continues regulate product labeling prohibits promotion products unapproved offlabel uses along labeling restrictions outside united states abbvie subject similar regulatory requirements outside united states approval marketing pharmaceutical products abbvie must obtain approval clinical trial application product applicable supervising regulatory authorities commence clinical trials marketing product target markets approval requirements process country vary time required obtain approval may longer shorter required fda approval united states example abbvie may submit marketing authorizations european union either centralized decentralized procedure centralized procedure mandatory approval biotechnology products many pharmaceutical products provides single marketing authorization valid european union member states centralized procedure single marketing authorization application submitted european medicines agency agency evaluates application makes recommendation european commission makes final determination whether approve application decentralized procedure provides mutual recognition individual national approval decisions available products subject centralized procedure japan applications approval new product made pharmaceutical medical devices agency pmda japanspecific trials andor bridging studies demonstrate nonjapanese clinical data applies japanese patients may required completing comprehensive review pmda reports ministry health labour welfare approves denies application similarly applications new product china submitted center drug evaluation national medical products administration technical review approval product marketing china clinical data chinese subjects usually required support approval china requiring inclusion china global pivotal studies separate chinaasian clinical trial regulatory process many emerging markets continues evolve many emerging markets including asia generally require regulatory approval obtained large developed market united states europe country begin complete regulatory review process similar requirements japan china certain countries notably south korea taiwan india russia also generally require clinical studies include data patients countries conducted order support local regulatory approval requirements governing conduct clinical trials product licensing also vary addition postapproval regulatory obligations adverse event reporting cgmp compliance generally apply may vary country example marketing authorization granted european union periodic safety reports must submitted pharmacovigilance measures may required risk management plans regulationcommercialization distribution manufacturing manufacturing marketing sale promotion distribution abbvie 's products subject comprehensive government regulation government regulation various national regional federal state local agencies united states countries addresses among matters inspection controls research laboratory procedures clinical investigations product approvals manufacturing labeling packaging marketing promotion pricing reimbursement sampling distribution quality control postmarketing surveillance record keeping storage disposal practices abbvie 's operations also affected trade regulations many countries limit import raw materials finished products laws regulations seek prevent corruption bribery marketplace including united states foreign corrupt practices act united kingdom bribery act provide guidance corporate interactions government officials require safeguards protection personal data addition abbvie subject laws regulations pertaining health care fraud abuse including state federal antikickback false claims laws united states prescription drug manufacturers abbvie also subject taxes well application product user fees compliance laws regulations costly materially affects abbvie 's business among effects health care regulations substantially increase time difficulty costs incurred obtaining maintaining approval market newly developed existing products abbvie expects compliance regulations continue require significant technical expertise capital investment ensure compliance failure comply delay release new product result regulatory enforcement actions seizure recall product suspension revocation authority necessary product 's production sale civil criminal sanctions including fines penalties addition regulatory initiatives abbvie 's business affected ongoing studies utilization safety efficacy outcomes health care products components regularly conducted industry participants government agencies others studies lead updates data regarding utilization safety efficacy previously marketed products cases studies resulted may future result discontinuance limitations marketing products domestically worldwide may give rise claims damages persons believe injured result use access human health care products continues subject oversight investigation action governmental agencies legislative bodies private organizations united states countries major focus cost containment efforts reduce health care costs also made private sector notably health care payers providers instituted various cost reduction containment measures abbvie expects insurers providers continue attempts reduce cost health care products outside united states many countries control price health care products directly indirectly reimbursement payment pricing coverage limitations compulsory licensing political budgetary pressures united states countries may also heighten scope severity pricing pressures abbvie 's products foreseeable future united states specifically us federal laws require pharmaceutical manufacturers pay certain statutorilyprescribed rebates state medicaid programs prescription drugs reimbursed state medicaid plans efforts states seek additional rebates may affect abbvie 's business similarly veterans health care act prerequisite participation medicaid federal health care programs requires manufacturers extend additional discounts pharmaceutical products various federal agencies including united states department veterans affairs department defense public health service entities institutions addition recent legislative changes would require similarly discounted prices offered tricare program beneficiaries veterans health care form kact also established b drug discount program requires pharmaceutical manufacturers provide products reduced prices various designated health care entities facilities united states states also generic substitution legislation requiring permitting dispensing pharmacist substitute different manufacturer 's generic version pharmaceutical product one prescribed addition federal government follows diagnosisrelated group drg payment system certain institutional services provided medicare medicaid implemented prospective payment system pps services delivered hospital outpatient nursing home home health settings drg pps entitle health care facility fixed reimbursement based diagnosis andor procedure rather actual costs incurred patient treatment thereby increasing incentive facility limit control expenditures many health care products medicare reimburses part b drugs based average sales price plus certain percentage account physician administration costs reduced hospital outpatient setting medicare enters contracts private plans negotiate prices patient administered medicine delivered part patient protection affordable care act health care education reconciliation act together affordable care act abbvie pays fee related pharmaceuticals sales government programs addition abbvie provides discount branded prescription drugs sold patients fall medicare part coverage gap donut hole affordable care act also includes provisions known physician payments sunshine act require manufacturers drugs biologics covered medicare medicaid record transfers value physicians teaching hospitals report data centers medicare medicaid services subsequent public disclosure similar reporting requirements also enacted state level united states increasing number countries worldwide either adopted considering similar laws requiring disclosure interactions health care professionals failure report appropriate data may result civil criminal fines andor penalties european union european union adopted directives legislation governing labeling advertising distribution supply pharmacovigilance marketing pharmaceutical products legislation provides mandatory standards throughout european union permits member states supplement standards additional regulations european governments also regulate pharmaceutical product prices control national health care systems fund large part cost products consumers result patients unlikely use pharmaceutical product reimbursed government many european countries government either regulates pricing new product launch subsequent launch direct price controls reference pricing recent years many countries also imposed new additional cost containment measures pharmaceutical products differences national pricing regimes create price differentials within european union lead significant parallel trade pharmaceutical products governments also promote generic substitution mandating permitting pharmacist substitute different manufacturer 's generic version pharmaceutical product one prescribed permitting mandating health care professionals prescribe generic versions certain circumstances many governments also following similar path biosimilar therapies addition governments use reimbursement lists limit pharmaceutical products eligible reimbursement national health care systems japan japan national health insurance system maintains drug price list specifying pharmaceutical products eligible reimbursement ministry health labour welfare sets prices products list government generally introduces price cut rounds every year also mandates price decreases specific products new products judged innovative useful indicated pediatric use target orphan small population diseases however may eligible pricing premium government also promoted use generics available emerging markets many emerging markets take steps reduce pharmaceutical product prices cases direct price controls others promotion genericbiosimilar alternatives branded pharmaceuticals since abbvie markets products worldwide certain products local nature variations product lines must also meet local regulatory requirements certain additional risks inherent conducting business outside united states including price currency exchange controls changes currency exchange rates limitations participation local enterprises expropriation nationalization governmental action regulation medical devices medical devices subject regulation fda state agencies foreign government health authorities fda regulations well various us federal state laws govern development clinical testing manufacturing labeling record keeping marketing medical device products agencies united states abbvies medical device product candidates including abbvies breast implants must undergo rigorous clinical testing extensive government regulatory clearance approval process prior sale united states countries lengthy process clinical development submissions clearance approval continuing need compliance applicable laws regulations require expenditure substantial resources regulatory clearance approval obtained may limited scope may significantly limit indicated uses product may marketed cleared approved products manufacturers subject ongoing review discovery previously unknown problems products may result restrictions manufacture sale andor use require withdrawal market united states abbvies medical device products subject extensive regulation fda united states unless exemption applies medical device abbvie markets united states must k clearance premarket approval application pma accordance ffdca implementing regulations fda classifies medical devices one three classes depending degree risk associated medical device extent controls needed ensure safety effectiveness devices deemed pose lower risk placed either class class ii devices deemed fda pose greatest risk lifesustaining lifesupporting implantable devices device deemed substantially equivalent previously cleared k device placed class iii general class iii device marketed united states unless fda approves device submission pma changes device subsequent initial fda approval must also reviewed approved fda majority abbvies medical device products including abbvies breast implants regulated class iii medical devices class iii device may significant additional obligations imposed conditions approval time takes obtain approval long compliance regulatory requirements assured periodic unannounced facility inspections fda regulatory authorities inspections may include manufacturing facilities abbvies subcontractors thirdparty manufacturers failure comply applicable regulatory requirements result enforcement action fda may include following sanctions warning letters untitled letters fines injunctions civil penalties recall seizure abbvie products operating restrictions partial suspension total shutdown production refusing abbvie request k clearance pma approval new products withdrawing k clearance pma approvals already granted criminal prosecution clinical trial almost always required support pma application sometimes required k premarket notification clinical trials generally require submission application investigational device exemption ide must supported appropriate data animal laboratory testing results showing safe test device humans testing protocol scientifically sound study sponsor must obtain approval ide fda must also obtain approval study institutional review board overseeing trial results clinical testing may sufficient obtain approval investigational device device approved manufacture distribution device remains subject continuing regulation fda including quality system regulation requirements involve design testing control documentation quality assurance procedures manufacturing process medical device manufacturers subcontractors required register establishments list manufactured devices fda subject periodic unannounced inspections fda certain state agencies compliance regulatory requirements manufacturers must also report fda devices may caused contributed death serious injury malfunctioned way could likely cause contribute death serious injury manufacturer conducts field correction product recall removal reduce risk health posed device remedy violation ffdca may present health risk fda continues regulate device labeling prohibits promotion products unapproved label uses along labeling restrictions european union medical device products marketed european union must comply requirements medical device regulation mdr came effect may mdr provides regulatory oversight respect design manufacture clinical trials labeling adverse event reporting medical devices ensure medical devices marketed european union safe effective intended uses medical devices comply mdr entitled bear conformit europenne marking evidencing compliance may marketed european union failure comply domestic international regulatory requirements could affect abbvies ability market sell abbvies products countries form kenvironmental matters abbvie believes operations comply material respects applicable laws regulations concerning environmental protection regulations federal state environmental laws impose stringent limitations emissions discharges environment various manufacturing operations abbvie 's capital expenditures pollution control approximately million operating expenditures approximately million capital expenditures pollution control estimated approximately million operating expenditures estimated approximately million abbott identified one many potentially responsible parties investigations andor remediations several locations united states including puerto rico comprehensive environmental response compensation liability act commonly known superfund locations transferred abbvie connection separation distribution abbvie become party investigations remediations abbott also engaged remediation several sites transferred abbvie connection separation distribution cooperation environmental protection agency similar agencies feasible predict certainty final costs related investigations remediation activities abbvie believes costs together expenditures maintain compliance applicable laws regulations concerning environmental protection material adverse effect company 's financial position cash flows results operations employees abbvie employed approximately employees countries january outside united states abbvie 's employees represented unions works councils abbvie believes good relations employees human capital management attracting retaining providing meaningful growth development opportunities abbvie 's employees critical company 's success making remarkable impact peoples lives around world abbvie leverages numerous resources identify enhance strategic leadership capability foster employee engagement create culture diverse talent productive engaged abbvie invests employees competitive compensation benefits employee support programs offers bestinclass development leadership opportunities abbvie developed deep talent base ongoing investment functional leadership training sourcing worldclass external talent ensuring sustainable talent pipeline abbvie continuously cultivates enhances working culture embraces equality diversity inclusion fundamental company 's mission attracting developing talent attracting developing highperforming talent essential abbvies continued success abbvie implements detailed talent attraction strategies emphasis stem skill sets diverse talent base critical skillsets including drug discovery clinical development market access business development abbvie also invested integrated inclusive practices across endtoend hiring process introduced inclusive recruitment live trainings requirement people leaders recruiters abbvie also invests competitive compensation benefits programs addition offering comprehensive suite benefits ranging medical dental coverage retirement disability life insurance programs abbvie also provides health promotion programs mental health awareness campaigns employee assistance programs several countries financial wellness support onsite health screenings immunizations several countries onsite fitness rehabilitation centers abbvie launched onsite health care clinics certain locations offering convenient affordable access quality healthcare flu shots vaccines addition abbvie employee assistance fund part abbvie foundation supports two programs global employees abbvie possibilities scholarship children employees annual meritbased scholarship use accredited colleges universities vocationaltechnical schools employee relief program financial assistance support short term needs employees faced largescale disasters eg hurricane individual disasters eg home fire financial hardship eg death spouse finally abbvie empowers managers teams tools tips guidelines effectively managing workloads managing teams distance supporting flexible work practices implemented work abbvie 's hybrid work model offering eligible employees predictable flexibility new abbvie employees given tailored onboarding experience faster integration support performance one abbvie 's mentorship programs allows employees selfnominate mentors mentees facilitates meaningful relationships supporting employees career development goals abbvie also provides structured broadbased development opportunities focusing highperformance skills leadership training abbvie 's talent philosophy holds leaders accountable building highperforming organization company provides development opportunities levels leadership abbvie 's learn develop perform program offers yearlong selfdirected leadership education supplemented tools resources leverages leaders role models teachers addition foundational success factor abbvie 's leadership pipeline company 's professional development programs attract graduates postgraduates postdoctoral talent participate formal development programs lasting three years objective strengthening functional leadership capabilities culture abbvies shared values transforming lives acting integrity driving innovation embracing diversity inclusion serving community form core company 's culture abbvie articulates behaviors associated values ways work core set working behaviors emphasize company achieves results equally important achieving ways work designed ensure every abbvie employee aware company 's cultural expectations abbvie integrates ways work talent processes forming basis assessing performance prioritizing development ultimately rewarding employees abbvie believes culture creates strong engagement measured regularly confidential thirdparty allemployee survey engagement supports abbvies mission making remarkable impact peoples lives equity equality diversity inclusion eedi cornerstone abbvies human capital management approach prioritize fostering inclusive diverse workforce recently abbvie adopted fiveyear equality diversity inclusion roadmap defines key global focus areas objectives associated initiatives includes implementation plans organized business function geography abbvies senior leaders adopted formal goals aligned executing strategy recent years abbvie 's board directors prioritized oversight abbvie 's response us racial justice movement including overseeing internal programs designed ensure abbvie attracting retaining developing diverse talent december women represented percent management positions globally united states percent abbvie 's workforce comprised members historically underrepresented populations increase abbvie committed pay equity conducts pay equity analyses annually critical component abbvie 's strategy instill inclusive mindset abbvie leaders employees company continues realize full value diverse workforce recruitment retirement abbvie 's employee resource groups also help company nurture inclusive culture building community creating connections opportunities mentoring professional development talent attraction networking abbvie reiterated commitment racial equality social justice among things expanding employee matching program donations civil rights nonprofits fostering racial equity reaffirming commitment clinical trial diversity additional information abbvie 's efforts racial equality social justice provided company 's website httpsabbviecomourcompanyequalityinclusiondiversityourcommitmenttoracialjusticehtml internet information copies abbvie 's annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act available free charge abbvie 's investor relations website investorsabbviecom soon reasonably practicable abbvie electronically files material furnishes securities exchange commission sec abbvie 's corporate governance guidelines outline directorship qualifications code business conduct charters abbvie 's audit committee compensation committee nominations governance committee public policy committee available abbvie 's investor relations website investorsabbviecom item risk factors carefully consider following risks information evaluating abbvie abbvie 's common stock following risks could materially adversely affect abbvie 's results operations financial condition cash flows risk factors generally separated two groups risks related abbvie 's business risks related abbvie 's common stock based information currently known abbvie believes following information identifies significant risk factors affecting categories risks however risks uncertainties abbvie faces limited set forth risk factors described may order importance probability occurrence additional risks uncertainties presently known abbvie abbvie currently believes immaterial may also adversely affect business addition past financial performance may reliable indicator future performance historical trends used anticipate results trends future periods form kif following risks uncertainties develops actual events events could material adverse effect abbvie 's business results operations financial condition cash flows case trading price abbvie 's common stock could decline risks related abbvie 's business expiration loss patent protection licenses including loss exclusivity humira increased competition biosimilars may adversely affect abbvie 's revenues operating earnings abbvie relies patent trademark intellectual property protection discovery development manufacturing sale products particular patent protection aggregate important abbvie 's marketing pharmaceutical products united states major markets outside united states patents covering abbvie products normally provide market exclusivity important profitability many abbvie 's products patents certain products expire abbvie could face competition lower priced generic biosimilar products expiration loss patent protection product typically followed promptly substitutes may significantly reduce sales product short amount time abbvie 's competitive position compromised generics biosimilars otherwise could material adverse effect abbvie 's business results operations addition proposals emerge time time legislation encourage early rapid approval generic drugs biosimilars proposals enacted law could increase impact generic competition large pharmaceutical companies generics manufacturers pharmaceutical products continue expand biotechnology field form partnerships pursue biosimilars companies developed developing biosimilars compete abbvies biologic products including humira competitors obtain marketing approval biosimilars referencing abbvies biologic products abbvies products may become subject competition biosimilars attendant competitive pressure consequences expiration successful challenges abbvies applicable patent rights could also trigger competition products assuming relevant exclusivity period expired result abbvie could face increased litigation administrative proceedings respect validity andor scope patents relating biologic products example humira accounted approximately abbvie 's total net revenues humira facing competition biosimilar products united states beginning due loss exclusivity abbvie anticipates cause significant decline humira 's revenue could adversely affect abbvies revenues operating earnings abbvie 's principal patents trademarks described greater detail item businessintellectual property protection regulatory exclusivity item management 's discussion analysis financial condition results operationsresults operations litigation regarding patents described item legal proceedings abbvie 's major products could lose patent protection earlier expected could adversely affect abbvie 's revenues operating earnings significant portion abbvie 's revenue operating earnings derived several major products third parties government authorities may challenge seek invalidate circumvent abbvie 's patents patent applications example manufacturers generic pharmaceutical products file may continue file abbreviated new drug applications fda seeking market generic forms abbvie 's products prior expiration relevant patents owned licensed abbvie asserting patents invalid unenforceable andor infringed addition petitioners filed may continue file challenges validity abbvie 's patents leahysmith america invents act created inter partes review post grant review procedures challenging patent validity administrative proceedings united states patent trademark office although challenges abbvie 's intellectual property come businesses governments may also challenge intellectual property rights example court decisions potential legislation relating patents legislation regarding biosimilars regulatory initiatives may result erosion intellectual property protection addition certain governments outside united states indicated compulsory licenses patents may sought domestic policies basis national emergencies hivaids triggered compulsory licenses may diminish eliminate sales profits jurisdictions negatively affect abbvie 's results operations abbvie normally responds challenges vigorously defending patents including filing patent infringement lawsuits patent litigation administrative proceedings challenges abbvie 's patents costly unpredictable may deprive abbvie market exclusivity patented product extent abbvie 's intellectual property successfully challenged circumvented weakened extent intellectual property allow abbvie compete effectively abbvie 's business suffer extent countries enforce abbvie 's intellectual property rights require compulsory licensing abbvie 's intellectual property abbvie 's revenues operating earnings reduced third party 's intellectual property may prevent abbvie selling products material adverse effect abbvie 's profitability financial condition third parties may claim abbvie product infringes upon intellectual property addition pursuit valid business opportunities abbvie may required challenge intellectual property rights held others believes improperly granted resolving intellectual property infringement claim costly time consuming may require abbvie enter license agreements abbvie guarantee would able obtain license agreements commercially reasonable terms successful claim patent intellectual property infringement could subject abbvie significant damages injunction preventing manufacture sale use affected abbvie product products events could material adverse effect abbvie 's profitability financial condition abbvie 's research development efforts may succeed developing marketing commercially successful products technologies may cause revenues profitability decline remain competitive abbvie must continue launch new products new indications andor brand extensions existing products launches must generate revenue sufficient cover substantial research development costs replace revenues profitable products lost displaced competing products therapies failure would material adverse effect abbvie 's revenue profitability accordingly abbvie commits substantial effort funds resources research development must make ongoing substantial expenditures without assurance efforts commercially successful high rate failure biopharmaceutical industry inherent research development new products failure occur point research development process including significant funds invested products appear promising development may fail reach market numerous reasons including failure demonstrate effectiveness safety concerns superior safety efficacy competing therapies failure achieve positive clinical preclinical outcomes beyond current standards care inability obtain necessary regulatory approvals delays approval new products new indications limited scope approved uses excessive costs manufacture failure obtain maintain intellectual property rights infringement intellectual property rights others decisions research studies made early development process pharmaceutical product candidate affect marketing strategy candidate receives approval detailed studies may demonstrate additional benefits help marketing also consume time resources may delay submitting pharmaceutical product candidate regulatory approval abbvie guarantee proper balance speed testing made respect pharmaceutical product candidate decisions area would adversely affect abbvie 's results operations even abbvie successfully develops markets new products enhancements existing products may quickly rendered obsolete changing clinical preferences changing industry standards competitors ' innovations abbvie 's innovations may accepted quickly marketplace existing clinical practices uncertainty thirdparty reimbursement abbvie state certainty whether products development launched whether able develop license otherwise acquire compounds products whether products commercially successful failure launch successful new products new indications existing products may cause abbvie 's products become obsolete causing abbvie 's revenues operating results suffer abbvie subject costcontainment efforts pricing pressures could cause reduction revenues operating earnings changes terms rebate chargeback programs common pharmaceuticals industry could material adverse effect abbvie 's operations costcontainment efforts governments private organizations described greater detail item businessregulationcommercialization distribution manufacturing extent cost containment efforts offset greater demand increased patient access health care factors abbvie 's revenues operating earnings reduced united states european union countries abbvie 's business experienced downward pressure product pricing pressure could increase future abbvie subject increasing public legislative pressure respect pharmaceutical pricing united states practices managed care groups institutional governmental purchasers well federal laws regulations related medicare medicaid contribute pricing pressures particular inflation reduction act form k requires government negotiate prices select high expenditure medicare part drugs prices effective beginning part b drugs prices effective beginning ii manufacturers pay rebate medicare part b part drugs prices drugs increase faster inflation beginning part part b iii medicare part redesign replacing current coverage gap provisions establishing cap outofpocket costs medicare beneficiaries beginning manufacturers responsible costs cap cap reached inflation reduction act implemented forthcoming agency action outcome reasonably determined certainty additionally changes us tax laws require minimum tax generally applied us corporations adjusted financial statement income beginning ii nondeductible excise tax provision net stock repurchases applied repurchases beginning abbvie continues evaluate impact inflation reduction act may company potential continuing changes health care system united states increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries may result additional pricing pressures major markets worldwide governments play significant role funding health care services determining pricing reimbursement pharmaceutical products consequently markets abbvie subject government decisionmaking budgetary actions respect products particular many european countries ongoing governmentmandated price reductions many pharmaceutical products abbvie anticipates continuing pricing pressures europe differences countries ' pricing regulations could lead thirdparty crossborder trading abbvie 's products results reduction revenues operating earnings rebates related government programs feeforservice medicaid medicaid managed care programs arise laws regulations abbvie predict certainty additional government initiatives contain health care costs factors could lead new modified regulatory requirements include higher incremental rebates discounts rebate discount programs arise contractual agreements private payers various factors including market factors ability private payers control patient access products may provide payers leverage negotiate higher additional rebates discounts could material adverse effect abbvie 's operations portion abbvie 's nearterm pharmaceutical pipeline relies collaborations third parties may adversely affect development sale products abbvie depends alliances joint ventures pharmaceutical biotechnology companies portion products nearterm pharmaceutical pipeline failures parties meet contractual regulatory obligations abbvie disruption relationships abbvie third parties could adverse effect abbvie 's pharmaceutical pipeline business addition abbvie 's collaborative relationships research development extend many years may give rise disputes regarding relative rights obligations revenues abbvie collaboration partners including ownership intellectual property associated rights obligations could result loss intellectual property rights protection delay development sale potential pharmaceutical products affect effective sale delivery abbvie 's commercialized products lead lengthy expensive litigation administrative proceedings arbitration biologics carry unique risks uncertainties could negative impact abbvie 's business results operations successful discovery development manufacturing sale biologics long expensive uncertain process unique risks uncertainties biologics example access supply necessary biological materials cell lines may limited current governmental regulations restrict access regulate transport use materials addition development manufacturing sale biologics subject regulations often complex extensive regulations applicable pharmaceutical products result manufacturing biologics especially large quantities often complex may require use innovative technologies manufacturing also requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures biologics also frequently costly manufacture production inputs derived living animal plant material biologics made synthetically failure successfully discover develop manufacture sell biologicsincluding humira skyrizi could negative impact abbvie 's business results operations new products technological advances abbvie 's competitors may negatively affect abbvie 's results operations abbvie competes researchbased pharmaceutical biotechnology companies research develop manufacture market sell proprietary pharmaceutical products biologics example humira competes anti tnf products competitive products intended treat number disease states mavyretmaviret competes available hepatitis c treatment options addition past years number companies started develop successfully developed andor currently marketing products positioned competitors botox competitors may introduce new products develop technological advances compete abbvies products therapeutic areas immunology hematologic oncology aesthetics neuroscience eye care addition abbvie products lose exclusivity competition surrounding products increase generic biosimilar products increasingly penetrate markets abbvie predict certainty timing impact introduction competitors new products technological advances competing products may safer effective effectively marketed sold lower prices better insurance coverage reimbursement levels superior performance features abbvies products may negatively impact abbvies business results operations manufacture many abbvie 's products highly exacting complex process abbvie one suppliers encounters problems manufacturing abbvie 's products abbvie 's business could suffer manufacture many abbvie 's products highly exacting complex process due part strict regulatory requirements problems may arise manufacturing variety reasons including equipment malfunction failure follow specific protocols procedures problems raw materials delays related construction new facilities expansion existing facilities including intended support future demand abbvie 's products changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could inhibit continuous supply manmade natural disasters environmental factors problems arise production batch product batch product may discarded abbvie may experience product shortages incur added expenses could among things lead increased costs lost revenue damage customer relations time expense spent investigating cause depending cause similar losses respect batches products problems discovered product released market recall product liability costs may also incurred abbvie uses raw materials components pharmaceutical biologic manufacturing processes including sourced single suppliers interruption supply raw materials components could adversely affect abbvie 's business results operations abbvie uses raw materials components pharmaceutical biologic manufacturing processes may sourced single suppliers failure abbvie 's suppliers particularly singlesource suppliers fulfill contractual obligations timely manner result regulatory noncompliance physical disruption manufacturing site may impair abbvie 's ability deliver products customers timely competitive basis could adversely affect abbvie 's business results operations increases demand abbvie 's suppliers could result delays disruptions manufacturing distribution sale products andor product shortages leading lost revenue finding alternative supplier could take significant amount time involve significant expense due nature products need obtain regulatory approvals abbvie guarantee able reach agreement alternative providers regulatory authorities would approve abbvie 's use alternatives business interruption insurance may provide adequate compensation case failure supplier certain aspects abbvies operations highly dependent upon third party service providers abbvie relies suppliers vendors third party service providers research develop manufacture commercialize promote sell products reliance third party manufacturers reduces abbvies oversight control manufacturing process third party providers subject legal regulatory requirements privacy security risks market risks failure critical third party service provider meet obligations could material adverse impact abbvies operations results third party service providers violated alleged violated laws regulations performance obligations abbvie possible abbvie could suffer financial reputational harm negative outcomes including possible legal consequences significant safety efficacy issues could arise abbvie 's products could material adverse effect abbvie 's revenues financial condition pharmaceutical products receive regulatory approval based data obtained controlled clinical trials limited duration following regulatory approval products used longer periods time many patients additional perhaps extensive studies may also conducted may sponsored abbvie could also sponsored competitors insurance companies government institutions scientists investigators interested parties new safety efficacy issues reported new scientific information becomes available including results postmarketing phase trials governments change standards regarding safety efficacy labeling abbvie may required amend form kthe conditions use product example abbvie may voluntarily provide required provide updated information product 's label narrow approved indication either could reduce product 's market acceptance safety efficacy issues abbvie product arise sales product could halted abbvie regulatory authorities regulatory action could taken regulatory authorities safety efficacy issues affecting suppliers ' competitors ' products also may reduce market acceptance similar abbvie products new data abbvie 's products products similar products could negatively impact demand abbvie 's products due actual perceived safety issues uncertainty regarding efficacy cases could result product withdrawal furthermore new data information including information product misuse may lead government agencies professional societies practice management groups organizations involved various diseases publish guidelines recommendations related use abbvie 's products use related therapies place restrictions sales guidelines recommendations may lead lower sales abbvie 's products abbvie subject product liability claims lawsuits may adversely affect business results operations reputation ordinary course business abbvie subject product liability claims lawsuits alleging abbvie 's current historical products products companies promotes resulted could result unsafe condition injury patients example lawsuits pending allergan abbvies subsidiary certain former officers alleging made misrepresentations omissions regarding allergans textured breast implants product liability claims lawsuits safety alerts product recalls regardless ultimate outcome may material adverse effect abbvie 's business results operations reputation ability attract retain customers consequences may also include additional costs decrease market share product question lower revenue exposure claims abbvie evaluates risks determined cost obtaining product liability insurance outweighs likely benefits coverage available abbvie 's product liability losses selfinsured abbvie also subject claims legal proceedings investigations ordinary course business relate intellectual property commercial securities matters adverse outcomes claims legal proceedings investigations may also adversely affect abbvies business results operations reputation example allergan named defendant approximately matters relating promotion sale prescription opioid pain relievers allergan recently agreed nationwide settlement resolve matters provide billion help support state local efforts address opioidrelated issues united states among things however abbvie guarantee conditions settlement satisfied additional suits filed see note legal proceedings contingencies consolidated financial statements included item financial statements supplementary data abbvie predict certainty outcome proceedings abbvie subject governmental regulations costly comply regulations develop compliant products processes abbvie 's products subject rigorous regulation numerous international supranational federal state authorities described item businessregulationdiscovery clinical development businessregulationcommercialization distribution manufacturing business regulationmedical devices process obtaining regulatory approvals market pharmaceutical product costly time consuming approvals may granted future products additional indications uses existing products timely basis delays receipt failure obtain approvals future products new indications uses could result delayed realization product revenues reduction revenues substantial additional costs us healthcare industry particular highly regulated subject frequent substantial regulatory changes expected us healthcare industry continue subject increasing regulation well political legal action future proposals reform healthcare system considered executive branch congress state legislatures abbvie predict certainty additional changes healthcare industry general pharmaceutical industry particular occur impact changes may example inflation reduction act implemented forthcoming agency action outcome reasonably determined certainty addition abbvie guarantee remain compliant applicable regulatory requirements approval obtained product requirements include among things regulations regarding manufacturing practices product labeling advertising postmarketing reporting including adverse event reports field alerts due manufacturing quality concerns abbvie must incur expense spend time effort ensure compliance complex regulations possible regulatory actions could result substantial modifications abbvie 's business practices operations refunds recalls seizures abbvie 's products total partial shutdown production one abbvie 's suppliers ' facilities abbvie supplier remedies alleged violation inability obtain future approvals withdrawals suspensions current products market events could disrupt abbvie 's business material adverse effect business results operations laws regulations affecting government benefit programs could impose new obligations abbvie require change business practices restrict operations health care industry subject federal state international laws regulations pertaining government benefit program reimbursements rebates price reporting regulation health care fraud abuse united states laws include antikickback false claims laws medicaid rebate statute veterans health care act us physician payments sunshine act tricare program government pricing rules applicable medicaid medicare part b b drug pricing program individual state laws relating pricing sales marketing practices violations laws regulations may punishable criminal andor civil sanctions including instances substantial fines imprisonment exclusion participation federal state health care programs including medicare medicaid veterans administration health programs violations may also lead product recalls seizures interruption production leading product shortages import bans denials import certifications delays denials approvals new products supplemental approvals current products pending resolution issues reputational harm would adversely affect abbvie 's business laws regulations broad scope subject change evolving interpretations could require abbvie incur substantial costs associated compliance alter one sales marketing practices addition violations laws regulations allegations violations could impose new obligations abbvie require change business practices restrict operations public health outbreaks epidemics pandemics coronavirus covid could future adverse impact abbvies operations financial condition public health outbreaks epidemics pandemics could future adverse impact abbvies operations financial condition pandemic caused novel strain coronavirus covid caused many countries including united states declare national emergencies implement preventive measures travel bans shelter place total lockdown orders continuation reimplementation bans orders remains uncertain covid pandemic caused abbvie modify certain business practices abbvie may take actions may required government authorities abbvie determines best interests abbvies employees patients customers business partners impact covid abbvies operations including among others manufacturing supply chain sales marketing commercial clinical trial operations date material abbvie experienced lower new patient starts certain products markets impact covid public health outbreaks abbvie longterm uncertain predicted confidence extent adverse impact covid public health outbreak abbvies operations depend extent severity continued spread disease globally timing nature actions taken respond resulting economic consequences ultimately efforts mitigate impact covid public health outbreak may completely prevent abbvie 's business adversely affected future impacts remain uncertain international nature abbvie 's business subjects additional business risks may cause revenue profitability decline abbvie 's business subject risks associated business internationally including emerging markets net revenues outside united states made approximately abbvie 's total net revenues risks associated abbvie 's operations outside united states include fluctuations currency exchange rates changes medical reimbursement policies programs pricing restrictions multiple legal regulatory requirements subject change could restrict abbvie 's ability manufacture market sell products differing local product preferences product requirements trade protection measures import export licensing requirements international trade disruptions disputes difficulty establishing staffing managing operations differing labor regulations potentially negative consequences changes interpretations tax laws political economic instability including result covid pandemic sovereign debt issues price currency exchange controls limitations participation local enterprises expropriation nationalization governmental action regulation inflation recession fluctuations interest rates restrictions transfers funds potential deterioration economic position credit quality certain nonus countries potential penalties adverse consequences violations anticorruption antibribery similar laws regulations including united states foreign corrupt practices act united kingdom bribery act particular february armed conflict escalated russia ukraine response thereto united states north atlantic treaty organizations member states well certain nonmember states announced targeted economic sanctions embargoes export controls russia belarus although abbvie continuing supply essential pharmaceutical products russia humanitarian reasons working maintain compliance evolving international sanctions suspended operations aesthetics products russia abbvie 's operations russia belarus ukraine significant however possible predict certainty continued consequences conflict addition sanctions included regional instability geopolitical shifts adverse effects macroeconomic conditions currency exchange rates financial markets consequences could adverse impact abbvie 's business results operations abbvie effectively profitably commercialize products abbvie 's revenues financial condition could adversely affected abbvie must effectively profitably commercialize principal products creating meeting continued market demand achieving market acceptance generating product sales ensuring active pharmaceutical ingredients product finished product manufactured sufficient quantities compliance requirements fda similar foreign regulatory agencies acceptable quality pricing meet commercial demand ensuring entire supply chain efficiently consistently delivers abbvie 's products customers commercialization abbvie products may successful due among things unexpected challenges competitors new safety issues concerns reported may impact narrow approved indications relative price abbvie 's product compared alternative treatment options changes product 's label restrict marketing commercialization abbvie 's principal products unsuccessful abbvie 's revenues financial condition could adversely affected abbvie may acquire businesses license rights technologies products form alliances dispose assets could cause incur significant expenses could negatively affect profitability abbvie may pursue acquisitions technology licensing arrangements joint ventures strategic alliances dispose assets part business strategy abbvie may complete transactions timely manner costeffective basis may realize expected benefits abbvie successful making acquisition products technologies acquired may successful may require significantly greater resources investments originally anticipated abbvie may able integrate acquisitions successfully existing business could incur assume significant debt unknown contingent liabilities abbvie could also experience negative effects reported results operations acquisition dispositionrelated charges amortization expenses related intangibles charges impairment longterm assets effects could cause deterioration abbvie 's credit rating result increased borrowing costs interest expense additionally changes abbvie 's structure operations revenues costs efficiency resulting major transactions acquisitions divestitures mergers alliances joint ventures restructurings strategic initiatives may result greater expected costs may take longer expected complete encounter difficulties including need regulatory approval appropriate abbvie dependent wholesale distributors distribution products united states accordingly business results operations could adversely affected encounter financial difficulties three wholesale distributors mckesson corporation cardinal health inc amerisourcebergen corporation accounted substantially abbvie 's pharmaceutical product sales united states one significant wholesale distributors encounters financial difficulties distributor may decrease amount business abbvie abbvie may unable collect amounts distributor owes timely basis could adversely affect abbvie 's business results operations abbvie debt obligations could adversely affect business ability meet obligations amount debt abbvie incurred intends incur could important consequences abbvie investors consequences include among things requiring portion abbvie 's cash flow operations make interest payments debt reducing cash flow available fund capital expenditures corporate purposes grow abbvie 's business extent abbvie incurs additional indebtedness interest rates increase risks could increase addition abbvie 's cash flow operations may sufficient repay outstanding debt becomes due abbvie may able borrow money sell assets otherwise raise funds acceptable terms refinance debt abbvie may need additional financing future meet capital needs make opportunistic acquisitions financing may available favorable terms abbvie may need additional financing future meet capital needs make opportunistic acquisitions example may need increase investment research development activities capital credit markets may experience extreme volatility disruption may lead uncertainty liquidity issues borrowers investors abbvie may unable obtain desired additional financing terms favorable abbvie loses investment grade credit rating adequate funds available acceptable terms abbvie may unable fund expansion successfully develop enhance products respond competitive pressures could negatively affect abbvie 's business abbvie raises additional funds issuing debt entering credit facilities may subject limitations operations due restrictive covenants failure comply covenants could adversely affect abbvie 's business abbvie depends information technology failure significant disruption systems could material adverse effect abbvie 's business abbvie relies sophisticated software applications complex information technology systems operate business may vulnerable malicious intrusion random attack loss data privacy disruption degradation breakdown data privacy security breaches employees others may future result failure critical business operations breaches may cause sensitive data including intellectual property trade secrets personal information belonging abbvie patients customers business partners exposed unauthorized persons public date neither abbvies business operations materially impacted incidents although abbvie invested protection data information technology monitors systems ongoing basis assurance efforts prevent material breakdowns breaches abbvie 's information technology systems could material adverse effect abbvie 's business adverse consequences could include loss revenue loss critical sensitive information abbvies thirdparty providers databases systems could also result legal financial reputational business harm abbvie potentially substantial remediation costs addition abbvie maintains cyber insurance guarantee insurance sufficient cover financial legal business reputational losses may result interruption breach abbvie systems abbvies balances intangible assets including developed product rights goodwill acquired subject impairment testing may result impairment charges may adversely affect abbvies results operations financial condition significant amount abbvies total assets related acquired intangibles goodwill december carrying value abbvies developed product rights intangible assets billion carrying value abbvies goodwill billion abbvies developed product rights stated cost less accumulated amortization abbvie determines original fair value amortization periods developed product rights based assessment various factors impacting estimated form kuseful lives cash flows acquired products significant adverse changes factors require abbvie perform impairment test affected asset evidence impairment exists require abbvie take impairment charge respect asset assets impaired abbvie may adjust remaining useful lives charge could adversely affect abbvies results operations financial condition abbvies significant intangible assets include inprocess research development iprd intangible projects acquired recent business combinations indefinitelived intangible assets iprd assets risk failure significant certainty assets ultimately yield successful products abbvie 's ability realize value significant investments often contingent upon among things regulatory approvals market conditions iprd assets may become impaired andor written point future associated research development effort abandoned curtailed goodwill abbvies iprd intangible assets tested impairment annually events occur circumstances change could potentially reduce fair value reporting unit intangible asset impairment testing compares fair value reporting unit intangible asset carrying amount goodwill iprd impairment would recorded operating income could material adverse effect abbvies results operations financial condition failure attract develop retain highly qualified personnel could affect abbvies ability successfully develop commercialize products abbvies success largely dependent continued ability attract develop retain diverse highly qualified scientific technical management personnel well personnel expertise clinical research development governmental regulation commercialization competition qualified personnel biopharmaceutical field intense increasing abbvie sure able attract retain quality personnel costs materially increase illegal distribution sale third parties counterfeit unregistered versions abbvie products could material adverse impact reputation business results operations third parties may illegally obtain distribute sell counterfeit illegally diverted intended market versions abbvie products versions product would meet abbvie 's rigorous manufacturing testing distribution quality standards patient receives counterfeit stolen diverted drug may risk number dangerous health consequences prevalence counterfeitdiverted medicines industrywide issue due variety factors including adoption ecommerce increased covid pandemic greatly enhancing consumers ' ability obtain prescriptions medical treatments via internet lieu traditional brick mortar pharmacies expose patients greater risks internet preferred vehicle dangerous counterfeitdiverted product offers scams anonymity affords abbvie 's reputation business could suffer harm result counterfeit diverted drugs sold brand name may also result reduced revenues could negatively affect results operation factors material adverse effect abbvie 's profitability financial condition many factors affect abbvie 's results operations cash flows financial condition including changes interpretations laws regulations including changes accounting standards taxation requirements product marketing application standards data privacy laws particularly european union united states environmental laws differences fair value measurement assets liabilities actual value particularly pension postemployment benefits stockbased compensation intangibles goodwill contingent liabilities litigation contingent consideration absence recorded amount amount recorded minimum compared actual amount changes rate inflation including cost raw materials commodities supplies interest rates market value abbvie 's equity investments performance investments held employee benefit trusts changes creditworthiness counterparties transact business provide services abbvie employee benefit trusts environmental liabilities connection abbvies manufacturing processes distribution logistics including handling hazardous materials changes ability third parties provide information technology accounting human resources payroll outsourced services abbvie meet contractual obligations abbvie failure perceived failure achieving environmental social governance objectives information loss damage abbvie 's reputation brand image goodwill due increased use social media platforms business interruptions stemming natural disasters climate change earthquakes hurricanes flooding fires efforts taken third parties prevent mitigate disasters changes business economic political conditions including war political instability terrorist attacks threat future terrorist activity related military action natural disasters cost availability insurance due foregoing events labor disputes strikes slow downs forms labor union activity pressure thirdparty interest groups risks related abbvie 's common stock abbvie guarantee timing amount payment dividends common stock repurchase common stock although abbvie expects pay regular cash dividends timing declaration amount payment future dividends stockholders fall within discretion abbvie 's board directors board 's decisions regarding payment dividends depend many factors abbvie 's financial condition earnings capital requirements debt service obligations industry practice legal requirements regulatory constraints factors board deems relevant information see item market registrant 's common equity related stockholder matters issuer purchases equity securities abbvie 's ability pay dividends repurchase shares share repurchase program depend ongoing ability generate cash operations access capital markets abbvie guarantee continue pay dividend future abbvie stockholder 's percentage ownership abbvie may diluted future future stockholder 's percentage ownership abbvie may diluted equity issuances capital market transactions equity awards abbvie granting abbvie 's directors officers employees acquisitions purposes abbvie 's employees options purchase shares common stock result conversion abbott stock options whole part abbvie stock options abbvie anticipates compensation committee grant additional stock options stockbased awards employees awards dilutive effect abbvie 's earnings per share could adversely affect market price abbvie 's common stock time time abbvie issue additional options stockbased awards employees abbvie 's employee benefits plans addition abbvie 's amended restated certificate incorporation authorizes abbvie issue without approval abbvie 's stockholders one classes series preferred stock designation powers preferences relative participating optional special rights including preferences abbvie 's common stock respecting dividends distributions abbvie 's board directors generally may determine terms one classes series preferred stock could dilute voting power reduce value abbvie 's common stock example abbvie could grant holders preferred stock right elect number abbvie 's directors events happening specified events right veto specified transactions similarly repurchase redemption rights liquidation preferences abbvie could assign holders preferred stock could affect residual value common stock certain provisions abbvie 's amended restated certificate incorporation amended restated bylaws delaware law may prevent delay acquisition abbvie could decrease trading price abbvie 's common stock abbvie 's amended restated certificate incorporation amended restated bylaws contain delaware law contains provisions intended deter coercive takeover practices inadequate takeover bids encouraging prospective acquirors negotiate abbvie 's board directors rather attempt hostile takeover provisions include among others inability abbvie 's stockholders call special meeting division abbvie 's board directors three classes directors class serving staggered threeyear term provision stockholders may remove directors cause ability abbvie 's directors stockholders fill vacancies abbvie 's board directors requirement affirmative vote stockholders holding least abbvie 's voting stock required amend certain provisions abbvie 's amended restated certificate incorporation abbvie 's amended restated bylaws relating number term election abbvie 's directors filling board vacancies calling special meetings stockholders director officer indemnification provisions addition section delaware general corporation law provides subject limited exceptions persons acquire affiliated person acquires outstanding voting stock delaware corporation shall engage business combination corporation including merger consolidation acquisitions additional shares threeyear period following date person affiliates becomes holder corporation 's outstanding voting stock abbvie believes provisions protect stockholders coercive otherwise unfair takeover tactics requiring potential acquirors negotiate abbvie 's board directors providing abbvie 's board directors time assess acquisition proposal provisions intended make company immune takeovers however provisions apply even offer may considered beneficial stockholders could delay prevent acquisition abbvie 's board directors determines best interests abbvie abbvie 's stockholders provisions may also prevent discourage attempts remove replace incumbent directors cautionary statement regarding forwardlooking statements annual report contains certain forwardlooking statements regarding business strategies market potential future financial performance matters words believe expect anticipate project similar expressions uses future conditional verbs generally identify forward looking statements speak date statements made matters discussed forwardlooking statements subject risks uncertainties factors could cause actual results differ materially expressed implied forwardlooking statements particular information included item business item risk factors item management 's discussion analysis financial condition results operations contain forward looking statements forward looking statement expectation belief future results events expressed implied expectation belief based current plans expectations abbvie management expressed good faith believed reasonable basis assurance expectation belief result achieved accomplished factors could cause actual results events differ materially anticipated include limited matters described item risk factors item management 's discussion analysis financial condition results operations abbvie undertake specifically declines obligation update forwardlooking statements included annual report reflect events circumstances date hereof unless abbvie required applicable securities law item b unresolved staff comments none item properties abbvie 's corporate offices located north waukegan road north chicago illinois december abbvie owns leases approximately facilities worldwide containing aggregate approximately million square feet floor space dedicated production distribution administration abbvie 's significant manufacturing facilities following locations united states outside united states abbott park illinois campoverde di aprilia italy barceloneta puerto rico clonshaugh ireland branchburg new jersey la aurora costa rica campbell california ludwigshafen germany cincinnati ohio pringy france dublin california singapore irvine california sligo ireland north chicago illinois westport ireland waco texas worcester massachusetts wyandotte michigan leased property abbvie believes facilities suitable provide adequate production capacity current projected operations material encumbrances abbvie 's owned properties united states including puerto rico abbvie two central distribution centers abbvie also research development facilities united states located abbott park illinois branchburg new jersey cambridge massachusetts irvine california madison new jersey north chicago illinois pleasanton california santa cruz california south san francisco california worcester massachusetts outside united states abbvie 's principal research development facilities located ludwigshafen germany form kitem legal proceedings information pertaining legal proceedings provided note legal proceedings contingencies consolidated financial statements included item financial statements supplementary data incorporated reference herein item mine safety disclosures applicable information executive officers following table lists abbvie 's executive officers name age position richard gonzalez chairman board chief executive officer robert michael vice chairman president scott reents executive vice president chief financial officer timothy j richmond executive vice president chief human resources officer azita salekigerhardt phd executive vice president operations perry c siatis executive vice president general counsel secretary jeffrey r stewart executive vice president chief commercial officer thomas j hudson md senior vice president research development chief scientific officer elaine k sorg senior vice president abbvie president us commercial operations carrie strom senior vice president abbvie president global allergan aesthetics brian l durkin vice president controller mr gonzalez chairman chief executive officer abbvie served abbotts executive vice president pharmaceutical products group july december responsible abbotts worldwide pharmaceutical business including commercial operations research development manufacturing also served president abbott ventures inc abbotts medical technology investment arm mr gonzalez joined abbott held various management positions first appointed abbvie corporate officer december mr michael abbvies vice chairman president mr michael previously served vice chairman finance commercial operations chief financial officer june june executive vice president chief financial officer senior vice president chief financial officer vice president controller served abbvies vice president treasurer vice president controller commercial operations vice president financial planning analysis abbott mr michael served division controller nutrition supply chain mr michael joined abbott first appointed abbvie corporate officer march mr reents abbvies executive vice president chief financial officer previously served senior vice president chief financial officer june november vice president tax treasury june vice president tax mr reents joined abbott first appointed abbvie corporate officer june mr richmond abbvies executive vice president chief human resources officer served senior vice president human resources mr richmond served abbotts divisional vice president compensation benefits group vice president talent rewards divisional vice president talent acquisition mr richmond joined abbott first appointed abbvie corporate officer december dr salekigerhardt abbvies executive vice president operations served senior vice president operations dr salekigerhardt served abbotts vice president pharmaceuticals manufacturing supply divisional vice president quality assurance global pharmaceutical operations dr salekigerhardt joined abbott first appointed abbvie corporate officer december serves board entegris inc mr siatis abbvies executive vice president general counsel secretary mr siatis previously served senior vice president deputy general counsel september october mr siatis also served various roles including senior vice president legal chief ethics compliance officer senior vice president legal transactions rdalliance management chief ethics compliance officer vice president biologic strategic development legal regulatory mr siatis joined abbott first appointed abbvie corporate officer october mr stewart abbvies executive vice president chief commercial officer previously served senior vice president us commercial operations abbvies president commercial operations form k prior abbvies separation abbott served vice president abbott proprietary pharmaceutical division united states mr stewart joined abbott first appointed abbvie corporate officer december dr hudson abbvie 's senior vice president research development chief scientific officer previously served vice president head oncology discovery early development prior joining abbvie dr hudson served ontario institute cancer research president scientific director also previously served founder director mcgill university genome quebec innovation centre assistant director whiteheadmit center genome research dr hudson first appointed abbvie corporate officer july ms sorg abbvies senior vice president abbvie president us commercial operations previously served abbvies president us immunology patient services vice president immunology oncology served vice president immunology prior abbvies separation abbott abbvie ms sorg joined abbott first appointed abbvie corporate officer november prior joining abbott ms sorg served management roles eli lilly company years ms strom abbvies senior vice president abbvie president global allergan aesthetics responsible worldwide operations aesthetics franchise appointed position upon abbvies acquisition allergan first appointed abbvie corporate officer may allergan ms strom previously served senior vice president us medical aesthetics joined allergan mr durkin abbvies vice president controller mr durkin previously served vice president internal audit prior joining abbvie served vice president finance division controller abbotts vision care business controller pharmaceutical research development mr durkin joined abbott first appointed abbvie corporate officer october executive officers abbvie elected annually board directors officers elected board appointed chairman board officers either elected first meeting board directors held annual stockholder meeting appointed chairman board board meeting officer holds office successor duly elected appointed qualified officer 's death resignation removal family relationships executive officers listed part ii item market registrant 's common equity related stockholder matters issuer purchases equity securities principal market principal market abbvie 's common stock new york stock exchange symbol abbv abbvie 's common stock also listed chicago stock exchange traded various regional electronic exchanges stockholders stockholders record abbvie common stock january performance graph following graph compares cumulative total returns abbvie sp index nyse arca pharmaceuticals index period december december graph assumes invested abbvie common stock index december also assumes reinvestment dividends stock price performance following graph necessarily indicative future stock price performance performance graph furnished shall deemed filed sec subject section securities exchange act shall deemed incorporated reference abbvie 's filings securities act amended form kdividends october abbvie 's board directors declared increase quarterly cash dividend per share per share payable february stockholders record january timing declaration amount payment dividends abbvie future within discretion board directors depend upon many factors including abbvie 's financial condition earnings capital requirements operating subsidiaries covenants associated certain abbvie 's debt service obligations legal requirements regulatory constraints industry practice ability access capital markets factors deemed relevant board directors moreover abbvie determines pay dividend future assurance continue pay dividends amount dividends issuer purchases equity securities total number shares units total purchased part maximum number number average publicly approximate dollar value shares price announced shares units may units paid per share plans yet purchased period purchased unit programs plans programs october october november november december december total addition abbvie shares repurchased open market publicly announced program shares also included shares purchased open market benefit participants abbvie employee stock purchase plan october november december shares include shares surrendered abbvie satisfy minimum tax withholding obligations connection vesting exercise stockbased awards item reserved form kitem management 's discussion analysis financial condition results operations following discussion analysis financial condition abbvie inc abbvie company commentary read conjunction consolidated financial statements accompanying notes appearing item financial statements supplementary data section generally discusses items yeartoyear comparisons discussions items yeartoyear comparisons included found management 's discussion analysis financial condition results operations part ii item companys annual report fiscal year ended december executive overview company overview abbvie global diversified researchbased biopharmaceutical company positioned success comprehensive product portfolio leadership positions across immunology oncology aesthetics neuroscience eye care abbvie uses expertise dedicated people unique approach innovation develop market advanced therapies address worlds complex serious diseases abbvie 's products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers abbvieowned distribution centers public warehouses certain products including aesthetic products devices also sold directly physicians licensed healthcare providers united states abbvie distributes pharmaceutical products principally independent wholesale distributors sales directly retailers pharmacies patients customers outside united states abbvie sells products primarily wholesalers distributors depending market works largely centralized national payers system agree reimbursement terms certain products comarketed copromoted companies abbvie operates single global business segment approximately employees financial results abbvie 's strategy focused delivering strong financial results maximizing benefits allergan acquisition advancing investing pipeline returning value shareholders ensuring strong sustainable growth business long term company 's financial performance included delivering worldwide net revenues billion operating earnings billion diluted earnings per share cash flows operations billion worldwide net revenues increased reported basis constant currency basis reflecting growth across immunology neuroscience aesthetics portfolios diluted earnings per share included following aftertax costs billion related amortization intangible assets ii billion change fair value contingent consideration liabilities iii billion charges related litigation matters iv million acquisition integration expenses v million related intangible asset impairment costs partially offset aftertax gain million related divestiture pylera benefit million related certain tax items additionally financial results reflected continued funding support stages abbvies pipeline assets continued investment abbvies onmarket brands following closing allergan acquisition abbvie implemented integration plan designed reduce costs integrate optimize combined organization result successful execution integration plan abbvie realized billion annual cost synergies achieve integration objectives abbvie incurred total cumulative charges billion costs consisted severance employee benefit costs cash severance noncash severance including accelerated equity award compensation expense retention termination benefits integration expenses recent global events russiaukraine response military conflict russia ukraine united states north atlantic treaty organization member states well certain nonmember states announced targeted economic sanctions export controls russia belarus include restrictions export transfer products containing certain toxins including botox russia belarus however abbvie prohibited continue sale essential pharmaceutical products help ensure patients receive uninterrupted supply medicines march abbvie announced suspension operations aesthetics products russia april abbvie also announced profits sales essential medicines russia donated support direct humanitarian relief efforts ukraine companys operations russia belarus ukraine significant conflict escalates results broader economic political concerns abbvies business could adversely impacted impact coronavirus disease covid response covid abbvie continues closely manage manufacturing supply chain resources around world help ensure patients continue receive uninterrupted supply medicines clinical trial sites monitored locally protect safety study participants staff employees impact covid abbvie 's operations date material abbvie continues experience lower new patient starts certain products markets abbvie expects matter could continue negatively impact results operations throughout duration pandemic extent covid may impact abbvie 's financial condition results operations remains uncertain dependent numerous evolving factors including measures taken authorities mitigate spread covid emergence new variants effectiveness vaccines therapeutics strategic objectives abbvie 's mission discover develop innovative medicines products solve serious health issues today address medical challenges tomorrow achieving toptier financial performance outstanding execution abbvie intends execute strategy advance mission number ways including maximizing benefits diversified revenue base multiple longterm growth drivers ii leveraging abbvie 's commercial strength international infrastructure across therapeutic areas ensuring strong commercial execution new product launches iii continuing invest expand pipeline support opportunities immunology oncology aesthetics neuroscience eye care well continued investment key market products iv generating substantial operating cash flows support investment innovative research development return cash shareholders via strong growing dividend also reducing debt addition abbvie anticipates several regulatory submissions data readouts key clinical trials next months abbvie expects achieve strategic objectives skyrizi rinvoq revenue growth driven increasing market share indication expansion advancing hematologic oncology portfolio increasing venclexta market share new indications strong commercial execution new product launches effectively managing market competitive challenges impacting imbruvica continuing investment global expansion aesthetics increasing market penetration botox juvederm collection neuroscience revenue growth driven vraylar botox therapeutic ubrelvy qulipta maximizing abbvie 's existing eye care portfolio effectively managing impact humira biosimilar erosion favorable impact pipeline products indications recently approved currently regulatory review approval expected products described greater detail section labeled research development included part item form kresearch development research innovation cornerstones abbvie 's business global biopharmaceutical company abbvie 's longterm success depends great extent ability continue discover develop innovative products acquire collaborate compounds currently development biotechnology pharmaceutical companies abbvie 's pipeline currently includes compounds devices indications development individually collaboration license agreements focused important specialties immunology oncology aesthetics neuroscience eye care programs approximately mid latestage development following sections summarize transitions significant programs midstage development latestage development well developments significant latestage registration programs abbvie expects multiple midstage programs transition latestage programs next months significant programs developments immunology skyrizi january abbvie announced us food drug administration fda approved skyrizi treatment adults active psoriatic arthritis june abbvie announced fda approved skyrizi treatment adults moderately severely active crohns disease november abbvie announced european commission ec approved skyrizi treatment adults moderately severely active crohn 's disease inadequate response lost response intolerant conventional biologic therapy rinvoq january abbvie announced fda approved rinvoq treatment moderate severe atopic dermatitis adults children years age older whose disease respond previous treatment well controlled pills injections including biologic medicines use pills injections recommended february abbvie announced topline results second phase induction study uexcel rinvoq patients moderate severe crohns disease inadequate response intolerant conventional biologic therapy met primary key secondary endpoints march abbvie announced fda approved rinvoq treatment adults moderately severely active ulcerative colitis uc inadequate response intolerance one tumor necrosis factor tnf blockers april abbvie announced fda approved rinvoq treatment adults active ankylosing spondylitis inadequate response intolerance one tnf blockers may abbvie announced positive topline results uendure phase maintenance study rinvoq adult patients moderate severe crohn 's disease inadequate response intolerant conventional biologic therapy results showed patients treated rinvoq achieved coprimary secondary endpoints one year compared placebo july abbvie announced ec approved rinvoq treatment adults moderately severely active uc inadequate response lost response intolerant either conventional therapy biologic agent july abbvie announced submission supplemental new drug application snda fda marketing authorization application maa ema rinvoq treatment adult patients moderately severely active crohns disease july abbvie announced ec approved rinvoq treatment adult patients active nonradiographic axial spondyloarthritis nraxspa october abbvie announced fda approved rinvoq treatment adults active nraxspa objective signs inflammation inadequate response intolerance tnf blocker therapy november abbvie announced ema 's committee medical products human use chmp adopted opinion following review benefitrisk medicines within jak inhibitor class treatment inflammatory diseases including rinvoq confirming recommendation pharmacovigilance risk assessment committee prac chmp recommend changes current rinvoq indication statements recommended updates dosage special warnings jak inhibitor products indicated treatment inflammatory diseases recommendations forwarded ec expected issue final decision oncology telisov january abbvie announced fda granted breakthrough therapy designation investigational telisotuzumab vedotin telisov treatment patients advancedmetastatic epidermal growth factor receptor wild type nonsquamous nonsmall cell lung cancer high levels cmet overexpression whose disease progressed platinumbased therapy may abbvie initiated phase clinical trial evaluate telisov versus docetaxel treatment patients previously treated cmet overexpressing epidermal growth factor receptor wild type advancedmetastatic nonsquamous nonsmall cell lung cancer epcoritamab march genmab genmab announced fda granted orphandrug designation investigational medicine epcoritamab duobodycdxcd treatment follicular lymphoma genmab abbvie codeveloping epcoritamab share commercial responsibilities us japan abbvie responsible global commercialization june abbvie genmab announced primary results large bcell lymphoma expansion cohort epcore nhl phase clinical trial evaluating epcoritamab investigational subcutaneous bispecific antibody study epcoritamab demonstrated efficacy durable responses patients previously received least two prior lines antilymphoma therapy including chimeric antigen receptor tcell therapy september abbvie genmab submitted biological license application bla fda epcoritamab treatment patients relapsedrefractory large bcell lymphoma october abbvie genmab submitted maa ema epcoritamab treatment patients relapsedrefractory diffuse large bcell lymphoma october abbvie initiated phase clinical trial evaluate epcoritamab combination rituximab lenalidomide compared rituximab lenalidomide patients relapsed refractory follicular lymphoma november abbvie announced fda accepted priority review bla epcoritamab treatment relapsedrefractory large bcell lymphoma imbruvica august abbvie announced fda approved use imbruvica treatment pediatric patients one year older chronic graft versus host disease failure one lines systemic therapy august national comprehensive cancer network nccn united states issued updated guidelines management chronic lymphocytic leukemia cll recategorizing imbruvica preferred regimen recommended regimen form kaesthetics juvederm collection february abbvie announced fda approved juvederm volbella xc improvement infraorbital hollows adults age august abbvie announced fda approved juvederm volux xc improvement jawline definition adults age moderate severe loss jawline definition bonte march abbvie initiated three phase clinical trials evaluate efficacy safety bonte agn treatment glabellar lines neuroscience vraylar december abbvie announced fda approved vraylar adjunctive therapy antidepressants treatment major depressive disorder adults qulipta march abbvie announced results phase progress trial qulipta preventive treatment chronic migraine adults met primary endpoint resulted significant improvements secondary endpoints adjustment multiple comparisons june abbvie submitted snda fda qulipta preventative treatment chronic migraine adults july abbvie submitted maa ema qulipta prophylactic treatment migraine adult patients least four migraine days per month abbv may abbvie submitted new drug application fda abbv foscarbidopafoslevodopa treatment motor fluctuations patients advanced parkinson 's disease results operations net revenues comparisons presented constant currency rates reflect comparative local currency net revenues prior year 's foreign exchange rates measure provides information change net revenues assuming foreign currency exchange rates changed prior current periods abbvie believes nongaap measure change net revenues constant currency rates used conjunction gaap measure change net revenues actual currency rates may provide complete understanding company 's operations facilitate analysis company 's results operations particularly evaluating performance one period another percent change actual currency rates constant currency rates years ended dollars millions united states international net revenues form kthe following table details abbvie 's worldwide net revenues percent change actual currency rates constant currency rates years ended december dollars millions immunology humira united states international total skyrizi united states international total rinvoq united states international total hematologic oncology imbruvica united states collaboration revenues total venclexta united states international total aesthetics botox cosmetic united states international total juvederm collection united states international total aesthetics united states international total neuroscience botox therapeutic united states international total vraylar united states international nm nm nm nm total duodopa united states international total ubrelvy united states qulipta united states nm nm neuroscience united states international total percent change actual currency rates constant currency rates years ended december dollars millions eye care lumiganganfort united states international total alphagancombigan united states international total restasis united states international total eye care united states international total key products mavyret united states international total creon united states linzessconstella united states international total total net revenues nm meaningful net revenues include allergan product revenues acquisition closing date may following discussion analysis abbvie 's net revenues product presented constant currency basis global humira sales increased primarily driven market growth across therapeutic categories partially offset direct biosimilar competition international markets united states humira sales increased primarily driven market growth across indications favorable pricing increase partially offset lower market share following corresponding market share gains skyrizi rinvoq internationally humira revenues decreased primarily driven direct biosimilar competition january humira lost exclusivity united states following loss exclusivity abbvie expects direct biosimilar competition humira net revenues decline united states abbvie continues pursue strategies maintain broad formulary access humira manage impact biosimilar erosion net revenues skyrizi increased primarily driven continued strong volume market share uptake since launch treatment plaque psoriasis well market growth net revenues also favorably impacted recent regulatory approvals expansion skyrizi treatment psoriatic arthritis crohns disease net revenues rinvoq increased primarily driven continued strong volume market share uptake since launch treatment moderate severe rheumatoid arthritis well market growth net revenues also favorably impacted recent regulatory approvals expansion rinvoq treatment psoriatic arthritis atopic dermatitis ankylosing spondylitis ulcerative colitis nonradiographic axial spondyloarthritis net revenues imbruvica represent product revenues united states collaboration revenues outside united states related abbvie 's share imbruvica profit abbvie 's global imbruvica revenues decreased result decreased market demand lower market share united states decrease net revenues also partially offset increased collaboration revenues net revenues venclexta increased primarily due continued expansion venclexta treatment patients cll acute myeloid leukemia form knet revenues botox cosmetic increased due sustained consumer demand united states moderated second half year economic pressures impacting consumer discretionary spending increased investment key international markets net revenues juvederm collection decreased due economic pressures impacting consumer discretionary spending increased pricing promotions support market international net revenues increased due increased investment key markets partially offset suspension aesthetic operations russia impact covid china net revenues botox therapeutic increased due market growth net revenues vraylar increased due higher market share market growth net revenues ubrelvy increased primarily due increased market share uptake since launch partially offset unfavorable pricing net revenues qulipta increased greater due strong volume market share uptake since launch preventative treatment episodic migraine adults net revenues mavyret decreased due continued disruption global hepatitis c virus markets due covid pandemic gross margin percent change years ended december dollars millions gross margin percent net revenues gross margin percentage net revenues increased compared gross margin percentage favorably impacted changes product mix partially offset intangible asset impairment charge million selling general administrative percent change years ended december dollars millions selling general administrative percent net revenues selling general administrative sga expenses percentage net revenues increased compared prior year primarily due unfavorable impact litigation reserve charges billion partially offset leverage revenue growth increased synergies realized research development acquired iprd milestones percent change years ended december dollars millions research development percent net revenues acquired iprd milestones rd expenses percentage net revenues decreased compared rd expense percentage favorably impacted increased scale combined company synergies realized purchase priority review vouchers third parties prior year well lower integration costs related acquisition allergan acquired iprd milestones expense represents upfront subsequent development milestone payments incurred prior regulatory approval acquire rights inprocess rd projects rd collaborations licensing arrangements asset acquisitions acquired iprd milestones expense included charge million related acquiring syndesi therapeutics sa charges related upfront payments totaling million development milestones million acquired iprd milestones expense included charge million related exercising company 's exclusive right acquire teneoone charge million related collaboration agreement regenxbio inc charges related upfront payments totaling million development milestones million see note consolidated financial statements additional information operating expense net operating expense net included onetime charge million related asset divested part allergan acquisition partially offset million income related sale worldwide commercial rights mature brand pylera operating expense net included million charge related extension calico life sciences llc collaboration see note consolidated financial statements additional information nonoperating expenses years ended december millions interest expense interest income interest expense net net foreign exchange loss expense net interest expense decreased compared primarily due lower average debt balance result deleveraging partially offset impact higher interest rates interest income increased compared primarily due impact higher interest rates expense net included charges related changes fair value contingent consideration liabilities billion billion fair value contingent consideration liabilities impacted passage time multiple inputs including probability success achieving regulatorycommercial milestones discount rates estimated amount future sales acquired products marketbased factors change fair value reflected higher estimated skyrizi sales driven stronger market share uptake passage time partially offset higher discount rates change fair value reflected higher estimated skyrizi sales driven stronger market share uptake favorable clinical trial results passage time partially offset higher discount rates income tax expense effective income tax rate negative effective income tax rates differed us statutory tax rate principally due impact foreign operations reflects impact lower income tax rates locations outside united states tax incentives puerto rico foreign tax jurisdictions business development activities changes fair value contingent consideration effective tax rates periods also reflected benefit us tax credits principally related research development credits orphan drug tax credit puerto rico excise tax credits puerto rico tax credits relate excise tax certain products manufactured puerto rico tax levied gross inventory purchases entities puerto rico included cost products sold consolidated statements earnings majority tax creditable us income tax purposes puerto rico enacted act puerto rico act allowing transition puerto rico excise tax levied gross inventory purchases incomebased tax beginning company completed transition requirements puerto rico act resulting remeasurement certain deferred tax assets liabilities based income tax rates expected reverse future net tax benefit remeasurement deferred taxes related puerto rico act million financial position liquidity capital resources years ended december millions cash flows provided used operating activities investing activities financing activities operating cash flows increased primarily due improved results operations resulting revenue growth lower income tax payments partially offset timing working capital operating cash flows also reflected abbvies contributions defined benefit plans million million form kinvesting cash flows included payments made capital expenditures million acquisitions investments million million cash consideration paid acquire djs antibodies ltd offset cash acquired net sales maturities investments securities totaling million investment cash flows included million cash consideration paid acquire soliton inc offset cash acquired payments made acquisitions investments billion capital expenditures million net purchases investment securities totaling million financing cash flows included repayment billion aggregate principal amount company 's senior notes billion aggregate principal amount company 's senior notes billion aggregate principal amount company 's senior notes billion aggregate principal amount company 's senior notes billion aggregate principal amount companys senior notes million aggregate principal amount company 's floating rate senior notes additionally financing cash flows included repayment billion floating term loan due may issuance new billion floating rate term loan part term loan refinancing february subsequent december company repaid billion floating rate threeyear term loan scheduled mature may financing cash flows included early repayments billion aggregate principal amount company 's principal notes billion aggregate principal amount company 's senior notes million aggregate principal amount company 's senior euro notes financing cash flows also included repayment million aggregate principal amount floating rate senior notes billion aggregate principal amount senior notes billion aggregate principal amount senior notes million aggregate principal amount floating rate senior notes maturity additionally financing cash flows included repayment billion floating rate term loan due may issuance new billion floating rate term loan part term loan refinancing september financing cash flows also included cash dividend payments billion billion increase cash dividend payments primarily driven increase dividend rate company 's stock repurchase authorization permits purchases abbvie shares time time openmarket private transactions managements discretion program time limit discontinued time abbvie repurchased million shares billion million shares million abbvie 's remaining stock repurchase authorization billion december february abbvie 's board directors authorized billion increase existing stock repurchase authorization commercial paper borrowings issued commercial paper borrowings outstanding december december abbvie may issue additional commercial paper retire commercial paper meet liquidity requirements needed credit risk abbvie monitors economic conditions creditworthiness customers government regulations funding domestically abroad abbvie regularly communicates customers regarding status receivable balances including payment plans obtains positive confirmation validity receivables abbvie establishes allowance credit losses equal estimate future losses contractual life outstanding accounts receivable abbvie may also utilize factoring arrangements mitigate credit risk although receivables included arrangements historically significant amount total outstanding receivables credit facility access capital credit ratings credit facility abbvie currently billion fiveyear revolving credit facility matures august credit facility enables company borrow funds unsecured basis variable interest rates contains various covenants december company compliance covenants commitment fees credit facility insignificant amounts outstanding company 's credit facility december december access capital company intends fund shortterm longterm financial obligations mature cash hand future cash flows operations ability issue additional debt company 's ability generate cash flows operations issue debt enter financing arrangements acceptable terms could adversely affected material decline demand company 's products solvency customers suppliers deterioration company 's key financial ratios credit ratings material unfavorable changes business conditions current time company believes sufficient financial flexibility issue debt enter financing arrangements attract longterm capital acceptable terms support company 's growth objectives credit ratings moodys investors service upgraded abbvie 's senior unsecured longterm credit rating baa baa affirmed prime shortterm credit rating revised outlook positive stable addition standard poor 's global ratings revised outlook positive stable affirmed longterm issuer credit rating bbb unfavorable changes ratings may adverse impact future financing arrangements however would affect companys ability draw credit facility would result acceleration scheduled maturities companys outstanding debt future cash requirements contractual obligations following table summarizes abbvie 's estimated material contractual obligations december millions total current longterm longterm debt including current portion interest longterm debta contingent consideration liabilitiesb includes estimated future interest payments longterm debt interest payments debt calculated future periods using forecasted interest rates effect end projected interest payments include related effects interest rate swap agreements certain projected interest payments may differ future based changes floating interest rates factors events projected interest payments pertain obligations agreements outstanding december see note consolidated financial statements additional information regarding company 's debt instruments note additional information interest rate swap agreements outstanding december b includes contingent consideration liabilities recorded fair value consolidated balance sheet potential contingent consideration payments exceed fair value recorded consolidated balance sheet included table contractual obligations see note consolidated financial statements additional information regarding liabilities abbvie enters certain unconditional purchase obligations commitments normal course business changes commitments would material impact companys ability meet either shortterm longterm future cash requirements income taxes future income tax cash requirements include onetime transition tax liability mandatory deemed repatriation previously untaxed earnings foreign subsidiaries resulting us tax reform enacted onetime transition tax liability billion december payable four future annual installments liabilities unrecognized tax benefits totaled billion december possible reliably estimate timing future cash outflows related liabilities see note consolidated financial statements additional information unrecognized tax benefits quarterly cash dividend october abbvie announced board directors declared increase quarterly cash dividend per share per share beginning dividend payable february stockholders record january reflects increase approximately previous quarterly rate timing form kdeclaration amount payment dividends abbvie future within discretion board directors depend upon many factors including abbvie 's financial condition earnings capital requirements operating subsidiaries covenants associated certain abbvie 's debt service obligations legal requirements regulatory constraints industry practice ability access capital markets factors deemed relevant board directors collaborations licensing arrangements abbvie enters collaborative licensing arrangements third parties may require future milestone payments third parties contingent upon achievement certain development regulatory commercial milestones individually arrangements insignificant one annual reporting period however milestones multiple products covered arrangements happen reached reporting period aggregate charge expense could material results operations period business perspective payments viewed positive signify product successfully moving development generating likely generate future cash flows product sales possible predict reasonable certainty whether milestones achieved timing achievement see note consolidated financial statements additional information collaboration arrangements critical accounting policies estimates preparation financial statements accordance generally accepted accounting principles united states requires use estimates assumptions affect reported amounts assets liabilities reported amounts revenue expenses summary company 's significant accounting policies included note consolidated financial statements certain policies considered critical significantly impact company 's financial condition results operations require difficult subjective complex judgments often result need make estimates effect matters inherently uncertain actual results may vary estimates revenue recognition abbvie recognizes revenue control promised goods services transferred companys customers amount reflects consideration abbvie expects entitled exchange goods services sales value add taxes collected concurrent revenue producing activities excluded revenue abbvie generates revenue primarily product sales majority sales company transfers control invoices customer recognizes revenue upon shipment customer rebates abbvie provides rebates pharmacy benefit managers state government medicaid programs insurance companies administer medicare drug plans wholesalers group purchasing organizations government agencies private entities rebate chargeback accruals accounted variable consideration recorded reduction revenue period related product sold provisions rebates chargebacks totaled billion billion billion rebate amounts typically based upon volume purchases using contractual statutory prices may vary product payer type rebate factors used calculations accrual rebate include identification products subject rebate applicable price terms estimated lag time sale payment rebate significant order establish rebate chargeback accruals company uses internal external data estimate level inventory distribution channel rebate claims processing lag time type rebate estimate rebate percentage net price company tracks sales product customer payer company evaluates inventory data reported wholesalers available prescription volume information product pricing historical experience factors order determine adequacy reserves abbvie regularly monitors reserves records adjustments rebate trends rebate programs contract terms legislative changes significant events indicate change reserve appropriate historically adjustments rebate accruals material net earnings following table analysis three largest accruals rebates chargebacks comprise approximately total consolidated rebate chargebacks recorded reductions revenues remaining rebate provisions charged gross revenues significant determination operating earnings medicaid managed medicare care wholesaler millions rebates rebates chargebacks balance december additionsa provisions payments balance december provisions payments balance december provisions payments balance december represents rebate accruals chargeback allowances assumed allergan acquisition allowances allowances include cash discounts product returns sales incentives adjustments accounted variable consideration recorded reduction revenue period related product sold reserves cash discounts sales incentives readily determinable company 's experience payment history fairly consistent product returns reliably estimated based company 's historical return experience cash discounts totaled billion billion billion allowances cash discounts significant pension postemployment benefits abbvie engages outside actuaries assist determination obligations costs pension postemployment benefit plans direct obligations abbvie valuation funded status net periodic benefit cost plans calculated using actuarial assumptions significant assumptions reviewed annually include discount rate expected longterm rate return plan assets health care cost trend rates disclosed note consolidated financial statements discount rate selected based current market rates highquality fixedincome investments december year abbvie employs yield curve approach countries robust bond market exists yield curve developed using highquality bonds yieldcurve approach reflects plans ' specific cash flows ie duration calculating benefit obligations applying corresponding individual spot rates along yield curve abbvie reflects plans ' specific cash flows applies corresponding individual spot rates along yield curve calculating service cost interest cost portions expense countries abbvie reviews various indices corporate bond government bond benchmarks estimate discount rate form kabbvie 's assumed discount rates significant effect amounts reported defined benefit pension postemployment plans december basis point change assumed discount rate would following effects abbvie 's calculation net periodic benefit costs projected benefit obligations december basis point millions brackets denote reduction increase decrease defined benefit plans net periodic benefit cost projected benefit obligation postemployment plans net periodic benefit cost projected benefit obligation expected longterm rate return based asset allocation historical performance current view expected future returns abbvie considers inputs longterm focus avoid shortterm market influences current longterm rate return plan assets plan supported historical performance trust 's actual target asset allocation abbvie 's assumed expected longterm rate return significant effect amounts reported defined benefit pension plans december used calculation net periodic benefit cost one percentage point change assumed expected longterm rate return plan assets would increase decrease net period benefit cost plans million health care cost trend rate selected reviewing historical trends current views projected future health care cost increases current health care cost trend rate supported historical trend experience plan assumed health care cost trend rates significant effect amounts reported health care plans december used calculation net periodic benefit cost income taxes abbvie accounts income taxes asset liability method provisions federal state foreign income taxes calculated reported pre tax earnings based current tax laws deferred taxes provided using enacted tax rates future tax consequences temporary differences differences financial statement carrying amount assets liabilities respective tax bases tax benefits carryforwards valuation allowance established maintained based currently available information likely portion deferred tax asset realized litigation company subject contingencies various claims legal proceedings investigations regarding product liability intellectual property commercial securities matters arise normal course business see note consolidated financial statements additional information loss contingency provisions recorded probable losses management 's best estimate loss best estimate made minimum loss contingency amount within probable range recorded accordingly abbvie often initially unable develop best estimate loss therefore minimum amount could zero recorded information becomes known either minimum loss amount increased resulting additional loss provisions best estimate made also resulting additional loss provisions occasionally best estimate amount changed lower amount events result expectation favorable outcome previously expected valuation goodwill intangible assets abbvie acquired may continue acquire significant intangible assets connection business combinations abbvie records fair value transactions involving purchase sale intangible assets occur companies pharmaceuticals industry valuations usually based discounted cash flow analysis incorporating stage completion discounted cash flow model requires assumptions timing amount future net cash flows risk cost capital terminal values market participants factors significantly affect value intangible asset process research development iprd acquired business combination capitalized indefinitelived intangible asset regulatory approval obtained time accounted definitelived asset amortized estimated useful life discontinuation point intangible asset written iprd acquired transactions business combinations expensed immediately unless deemed alternative future use payments made third parties subsequent regulatory approval capitalized amortized remaining useful life abbvie reviews recoverability definitelived intangible assets whenever events changes circumstances indicate carrying value asset may recoverable goodwill indefinitelived intangible assets reviewed impairment annually event occurs could result impairment see note consolidated financial statements additional information annually company tests goodwill impairment first assessing qualitative factors determine whether likely fair value less carrying amount factors considered assessment include general macroeconomic conditions conditions specific industry market cost factors overall financial performance whether sustained declines company 's share price company concludes likely fair value reporting unit less carrying amount quantitative impairment test performed abbvie tests indefinitelived intangible assets impairment first assessing qualitative factors determine whether likely fair value less carrying amount company concludes likely fair value less carrying amount quantitative impairment test performed quantitative impairment tests company uses estimated future cash flow approach requires significant judgment respect future volume revenue expense growth rates changes working capital use selection appropriate discount rate asset groupings assumptions estimates estimates assumptions used consistent company 's business plans market participant 's views use alternative estimates assumptions could increase decrease projected cash flows estimated fair value related intangible assets future changes estimates assumptions could material impact company 's results operations actual results may differ company 's estimates contingent consideration fair value measurements contingent consideration liabilities determined acquisition date based significant unobservable inputs including discount rate estimated probabilities timing achieving specified development regulatory commercial milestones estimated amount future sales acquired products contingent consideration liabilities revalued fair value subsequent reporting date related contingency resolved potential contingent consideration payments estimated applying probabilityweighted expected payment model contingent milestone payments monte carlo simulation model contingent royalty payments discounted present value changes fair value contingent consideration liabilities result changes one number inputs including discount rates probabilities achieving milestones time required achieve milestones estimated future sales significant judgment employed determining appropriateness certain inputs disclosed note consolidated financial statements changes inputs described could material impact company 's financial position results operations given period form kitem quantitative qualitative disclosures market risk company exposed risk earnings cash flows equity could adversely impacted changes foreign exchange rates interest rates certain derivative instruments used available costeffective basis hedge company 's underlying economic exposures see note consolidated financial statements additional information regarding company 's financial instruments hedging strategies foreign currency risk abbvie 's primary net foreign currency exposures euro japanese yen canadian dollar chinese yuan british pound following table reflects total foreign currency forward exchange contracts outstanding december weighted fair weighted fair average exchange carrying value average exchange carrying value december millions contract amount rate receivablepayable contract amount rate receivablepayable receive primarily us dollars exchange following currencies euro canadian dollar british pound chinese yuan japanese yen currencies na na total company estimates appreciation underlying currencies hedged levels us dollar variables held constant would decrease fair value foreign exchange forward contracts billion december realized appreciation would negatively affect earnings remaining life contracts however gains losses hedging instruments offset losses gains hedged transactions reduce earnings stockholders ' equity volatility relating foreign exchange appreciation believed reasonably possible nearterm change foreign currencies december company billion aggregate principal amount unsecured senior euro notes outstanding exposed foreign currency risk company designated foreign currency denominated notes hedges net investments certain foreign subsidiaries affiliates result foreign currency translation gains losses related euro notes included accumulated comprehensive loss see note consolidated financial statements additional information regarding senior euro notes note consolidated financial statements additional information regarding net investment hedging program interest rate risk company estimates increase interest rates basis points would adversely impact fair value abbvie 's interest rate swap contracts approximately million december realized fair value reduction would affect earnings remaining life contracts company estimates increase basis points longterm interest rates would decrease fair value longterm debt billion december basis point change believed reasonably possible nearterm change interest rates item financial statements supplementary data consolidated financial statements consolidated statements earnings consolidated statements comprehensive income consolidated balance sheets consolidated statements equity consolidated statements cash flows notes consolidated financial statements note background note summary significant accounting policies note supplemental financial information note earnings per share note licensing acquisitions arrangements note collaborations note goodwill intangible assets note integration restructuring plans note leases note debit credit facilities commitments contingencies note financial instruments fair value measures note postemployment benefits note equity note income taxes note legal proceedings contingencies note segment geographic area information note fourth quarter financial results unaudited report independent registered public accounting firm pcaob id form kabbvie inc subsidiaries consolidated statements earnings years ended december millions except per share data net revenues cost products sold selling general administrative research development acquired iprd milestones operating expense net total operating costs expenses operating earnings interest expense net net foreign exchange loss expense net earnings income tax expense income tax expense benefit net earnings net earnings attributable noncontrolling interest net earnings attributable abbvie inc per share data basic earnings per share attributable abbvie inc diluted earnings per share attributable abbvie inc weightedaverage basic shares outstanding weightedaverage diluted shares outstanding accompanying notes integral part consolidated financial statements abbvie inc subsidiaries consolidated statements comprehensive income years ended december millions net earnings foreign currency translation adjustments net tax expense benefit net investment hedging activities net tax expense benefit pension postemployment benefits net tax expense benefit cash flow hedging activities net tax expense benefit comprehensive income comprehensive income comprehensive income attributable noncontrolling interest comprehensive income attributable abbvie inc accompanying notes integral part consolidated financial statements form kabbvie inc subsidiaries consolidated balance sheets december millions except share data assets current assets cash equivalents shortterm investments accounts receivable net inventories prepaid expenses total current assets investments property equipment net intangible assets net goodwill assets total assets liabilities equity current liabilities shortterm borrowings current portion longterm debt finance lease obligations accounts payable accrued liabilities total current liabilities longterm debt finance lease obligations deferred income taxes longterm liabilities commitments contingencies stockholders ' equity common stock par value shares authorized shares issued december december common stock held treasury cost shares december december additional paidin capital retained earnings accumulated comprehensive loss total stockholders ' equity noncontrolling interest total equity total liabilities equity accompanying notes integral part consolidated financial statements abbvie inc subsidiaries consolidated statements equity common shares common treasury additional retained accumulated noncontrolling years ended december millions outstanding stock stock paidin capital earnings comprehensive loss interest total balance december net earnings attributable abbvie inc comprehensive income net tax dividends declared common shares equity awards issued acquisition allergan plc purchases treasury stock stockbased compensation plans change noncontrolling interest balance december net earnings attributable abbvie inc comprehensive income net tax dividends declared purchases treasury stock stockbased compensation plans change noncontrolling interest balance december net earnings attributable abbvie inc comprehensive income net tax dividends declared purchases treasury stock stockbased compensation plans change noncontrolling interest balance december accompanying notes integral part consolidated financial statements form kabbvie inc subsidiaries consolidated statements cash flows years ended december millions brackets denote cash outflows cash flows operating activities net earnings adjustments reconcile net earnings net cash operating activities depreciation amortization intangible assets deferred income taxes change fair value contingent consideration liabilities stockbased compensation acquired iprd milestones charges related collaborations gain divestitures noncash litigation reserve adjustments net cash payments impairment intangible assets net changes operating assets liabilities net acquisitions accounts receivable inventories prepaid expenses assets accounts payable liabilities income tax assets liabilities net cash flows operating activities cash flows investing activities acquisition businesses net cash acquired acquisitions investments acquisitions property equipment purchases investment securities sales maturities investment securities net cash flows investing activities cash flows financing activities proceeds issuance longterm debt repayments longterm debt finance lease obligations debt issuance costs dividends paid purchases treasury stock proceeds exercise stock options payments contingent consideration liabilities net cash flows financing activities effect exchange rate changes cash equivalents net change cash equivalents cash equivalents beginning year cash equivalents end year supplemental information interest paid net portion capitalized income taxes paid supplemental schedule noncash investing financing activities issuance common shares associated acquisitions businesses accompanying notes integral part consolidated financial statements abbvie inc subsidiaries notes consolidated financial statements note background background principal business abbvie inc abbvie company discovery development manufacturing sale broad line therapies address world 's complex serious diseases abbvie 's products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers abbvieowned distribution centers public warehouses certain products including aesthetic products devices also sold directly physicians licensed healthcare providers united states abbvie distributes pharmaceutical products principally independent wholesale distributors sales directly retailers pharmacies patients customers outside united states abbvie sells products primarily wholesalers distributors depending market works largely centralized national payers system agree reimbursement terms abbvie incorporated delaware april january abbvie became independent publiclytraded company result distribution abbott laboratories abbott outstanding common stock abbvie abbott 's shareholders may abbvie completed acquisition allergan plc allergan refer note additional information regarding acquisition note summary significant accounting policies use estimates consolidated financial statements prepared accordance us generally accepted accounting principles gaap necessarily include amounts based estimates assumptions management actual results could differ amounts significant estimates include amounts rebates pension postemployment benefits income taxes litigation valuation goodwill intangible assets contingent consideration liabilities financial instruments inventory accounts receivable exposures basis consolidation consolidated financial statements include accounts abbvie subsidiaries controlling interest maintained controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities abbvie determined primary beneficiary investments companies abbvie significant influence controlling interest accounted using equity method abbvie 's share earnings losses reported expense net consolidated statements earnings intercompany balances transactions eliminated abbvie revised classification development milestone expense associated licensing collaboration arrangements consolidated statements earnings milestone payments incurred prior regulatory approval previously included research development rd expense presented acquired iprd milestones expense consolidated statements earnings reclassification decreased rd expense increased acquired iprd milestones expense million million company believes presentation assists users financial statements better understand total upfront subsequent development milestone payments incurred acquire inprocess research development projects prior periods reclassified conform current period presentation certain reclassifications made conform prior period consolidated financial statements current period presentation revenue recognition abbvie recognizes revenue control promised goods services transferred companys customers amount reflects consideration abbvie expects entitled exchange goods services sales value add taxes collected concurrent revenue producing activities excluded revenue abbvie generates revenue primarily product sales majority sales company transfers control invoices customer recognizes revenue upon shipment customer company recognizes shipping handling costs form kexpense cost products sold company transfers control customer payment terms vary depending type location customer based customary commercial terms generally less one year abbvie adjust revenue effects significant financing component contracts abbvie expects period transfer good service collection one year less cash discounts rebates chargebacks sales incentives product returns certain adjustments accounted variable consideration provisions variable consideration based current pricing executed contracts government pricing legislation historical data provided period related revenues recorded rebate amounts typically based upon volume purchases using contractual statutory prices may vary product payer type rebate factors used calculation accrual include identification products subject rebate applicable price terms estimated lag time sale payment rebate significant addition revenue contracts customers company also recognizes certain collaboration revenues see note additional information related collaborations janssen biotech inc genentech inc additionally see note disaggregation revenue product geography research development expenses internal rd costs expensed incurred clinical trial costs incurred third parties expensed contracted work performed acquired iprd milestones expenses asset acquisition payments incurred prior regulatory approval acquire rights inprocess rd projects expensed acquired iprd milestones expense consolidated statements earnings unless project alternative future use costs include upfront development milestone payments related rd collaborations licensing arrangements asset acquisitions provide rights develop manufacture andor sell pharmaceutical products contingent development milestone payments due third parties prior regulatory approval payment obligations expensed milestone results achieved regulatory commercial milestone payments made third parties subsequent regulatory approval capitalized intangible assets amortized cost products sold remaining useful life related product business combinations abbvie utilizes acquisition method accounting business combinations method requires among things results operations acquired companies included abbvie 's results operations beginning acquisition date assets acquired liabilities assumed recognized fair value acquisition date excess fair value consideration transferred fair value net assets acquired recognized goodwill contingent consideration liabilities recognized estimated fair value acquisition date subsequent changes fair value contingent consideration liabilities recognized expense net consolidated statements earnings fair value assets acquired liabilities assumed certain cases may subject revision based final determination fair value period time exceed months acquisition date legal costs due diligence costs business valuation costs business acquisition costs expensed incurred business combination fair value iprd projects acquired capitalized accounted indefinitelived intangible assets underlying project receives regulatory approval point intangible asset accounted definitelived intangible asset discontinuation point intangible asset written rd costs incurred company acquisition expensed rd incurred collaborations arrangements company enters collaborative agreements third parties develop commercialize drug candidates collaborative activities may include joint research development commercialization new products abbvie generally receives certain licensing rights arrangements collaborations often require upfront payments may include additional milestone research development cost sharing royalty profit share payments contingent upon occurrence certain future events linked success asset development commercialization upfront payments associated collaborative arrangements subsequent payments made partner achievement development milestones prior regulatory approval expensed acquired iprd milestones expense consolidated statements earnings regulatory commercial milestone payments made partner subsequent regulatory approval capitalized intangible assets amortized cost products sold estimated useful life related asset royalties expensed cost products sold consolidated statements earnings incurred advertising costs associated advertising expensed incurred included selling general administrative sga expense consolidated statements earnings advertising expenses billion billion billion pension postemployment benefits abbvie records annual expenses relating defined benefit pension postemployment benefit plans based calculations utilize various actuarial assumptions including discount rates rates return assets compensation increases turnover rates health care cost trend rates abbvie reviews actuarial assumptions annual basis makes modifications assumptions based current rates trends actuarial gains losses deferred accumulated comprehensive income loss aoci net tax amortized remaining service attribution periods employees corridor method differences expected longterm return plan assets actual annual return generally amortized net periodic benefit cost fiveyear period income taxes income taxes accounted asset liability method provisions federal state foreign income taxes calculated reported pre tax earnings based current tax laws deferred taxes provided using enacted tax rates future tax consequences temporary differences differences financial statement carrying amounts assets liabilities respective tax bases tax benefits carryforwards valuation allowance established maintained based currently available information likely portion deferred tax asset realized cash equivalents cash equivalents include money market funds time deposits original maturities three months less investments investments consist primarily equity securities heldtomaturity debt securities marketable debt securities time deposits investments equity securities readily determinable fair values recorded fair value investments equity securities readily determinable fair values recorded cost remeasured fair value based certain observable price changes impairment events occur heldtomaturity debt securities recorded cost gains losses investments included expense net consolidated statements earnings investments marketable debt securities classified availableforsale recorded fair value unrealized holding gains losses net tax included aoci consolidated balance sheets realized time gains losses recognized earnings abbvie periodically assesses marketable debt securities impairment credit losses decline fair value marketable debt security due credit related factors allowance credit losses recorded corresponding charge expense net consolidated statements earnings abbvie determines noncredit related impairment occurred amortized cost basis investment net allowance credit losses written charge expense net consolidated statements earnings availableforsale investment 's unrealized loss reclassified aoci expense net consolidated statements earnings realized gains losses sales investments computed using firstin first method adjusted impairments credit losses recorded net earnings accounts receivable accounts receivable stated amortized cost less allowance credit losses allowance credit losses reflects best estimate future losses contractual life outstanding accounts receivable determined basis historical experience specific allowances known troubled accounts currently available information including customer financial condition current forecasted economic conditions form kinventories inventories valued lower cost firstin firstout basis market cost includes material conversion costs inventories consisted following december millions finished goods workinprocess raw materials inventories property equipment december millions land buildings equipment construction progress property equipment gross less accumulated depreciation property equipment net depreciation property equipment recorded straightline basis estimated useful lives assets estimated useful life buildings ranges years buildings include leasehold improvements amortized lesser remainder lease term useful life leasehold improvement estimated useful life equipment ranges years equipment includes certain computer software software development costs incurred connection developing obtaining software internal use amortized years depreciation expense million million million leases shortterm leases term months less recorded balance sheet leases commencing modified later abbvie separate lease components nonlease components company records lease liabilities based present value lease payments lease term abbvie generally uses incremental borrowing rate discount lease liabilities rate implicit lease typically readily determinable certain lease agreements include renewal options company 's control abbvie includes optional renewal periods lease term reasonably certain abbvie exercise option variable lease payments include payments lessors taxes maintenance insurance operating costs well payments adjusted based index rate company 's lease agreements contain significant residual value guarantees restrictive covenants litigation contingencies loss contingency provisions recorded probable liability incurred amount liability reasonably estimated based existing information best estimate made minimum loss contingency amount probable range recorded legal fees expensed incurred abbvie accrues product liability claims undiscounted basis liabilities evaluated quarterly adjusted necessary additional information becomes available receivables insurance recoveries product liability claims recorded assets undiscounted basis probable recovery realized goodwill intangible assets intangible assets acquired business combination recorded fair value using discounted cash flow model discounted cash flow model requires assumptions timing amount future net cash flows risk cost capital terminal values market participants definitelived intangibles amortized estimated useful lives using estimated pattern economic benefit abbvie reviews recoverability definitelived intangible assets whenever events changes circumstances indicate carrying value asset may recoverable abbvie first compares projected undiscounted cash flows generated asset carrying value undiscounted cash flows intangible asset less carrying value intangible asset written fair value cash flows identified individual asset review applied lowest level cash flows largely independent cash flows assets liabilities goodwill indefinitelived assets amortized subject impairment review annually frequently indicators impairment exist impairment goodwill could occur carrying amount reporting unit exceeded fair value reporting unit impairment indefinitelived intangible assets would occur fair value intangible asset less carrying value company tests goodwill impairment first assessing qualitative factors determine whether likely fair value less carrying amount company concludes likely fair value reporting unit less carrying amount quantitative impairment test performed abbvie tests indefinitelived intangible assets impairment first assessing qualitative factors determine whether likely fair value less carrying amount company concludes likely fair value less carrying amount quantitative impairment test performed quantitative impairment tests company uses estimated future cash flow approach requires significant judgment respect future volume revenue expense growth rates changes working capital use selection appropriate discount rate asset groupings assumptions estimates estimates assumptions used consistent company 's business plans market participant 's views use alternative estimates assumptions could increase decrease projected cash flows estimated fair value related intangible assets future changes estimates assumptions could material impact company 's results operations actual results may differ company 's estimates foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using periodend exchange rates us dollar affects arise translating net assets subsidiaries changing rates recognized comprehensive income loss consolidated statements comprehensive income net assets subsidiaries highly inflationary economies remeasured functional currency reporting currency remeasurement recognized net foreign exchange loss consolidated statements earnings derivatives derivative instruments recognized either assets liabilities fair value consolidated balance sheets classified current long term based scheduled maturity instrument derivatives formally designated hedges company assesses inception quarterly thereafter whether hedging derivatives highly effective offsetting changes fair value cash flows hedged item changes fair value derivative designated fair value hedge hedged item attributable hedged risk recognized earnings immediately effective portions changes fair value derivative designated cash flow hedge reported aoci subsequently recognized earnings consistent underlying hedged item determined derivative longer highly effective hedge company discontinues hedge accounting prospectively hedged forecasted transaction becomes probable occurring gains losses reclassified aoci earnings derivatives designated hedges adjusted fair value current earnings company also uses derivative instruments foreign currency denominated debt hedge net investments certain foreign subsidiaries affiliates realized unrealized gains losses hedges included aoci derivative cash flows exception net investment hedges principally classified operating section consolidated statements cash flows consistent underlying hedged item cash flows related net investment hedges classified investing section consolidated statements cash flows form knote supplemental financial information interest expense net years ended december millions interest expense interest income interest expense net accounts payable accrued liabilities december millions sales rebates dividends payable accounts payable current portion contingent consideration liabilities salaries wages commissions royalty license arrangements accounts payable accrued liabilities longterm liabilities december millions contingent consideration liabilities liabilities unrecognized tax benefits income taxes payable pension postemployment benefits longterm liabilities note earnings per share abbvie grants certain restricted stock units rsus considered participating securities due presence participating securities abbvie calculates earnings per share eps using dilutive treasury stock twoclass method periods presented twoclass method dilutive following table summarizes impact twoclass method years ended december millions except per share data basic eps net earnings attributable abbvie inc earnings allocated participating securities earnings available common shareholders weighted average basic shares common stock outstanding basic earnings per share attributable abbvie inc diluted eps net earnings attributable abbvie inc earnings allocated participating securities earnings available common shareholders weighted average shares common stock outstanding effect dilutive securities weighted average diluted shares common stock outstanding diluted earnings per share attributable abbvie inc certain shares issuable stockbased compensation plans excluded computation eps effect would antidilutive number common shares excluded insignificant periods presented form knote licensing acquisitions arrangements acquisition djs antibodies ltd october abbvie entered agreement acquire djs antibodies ltd djs including lead program djs proprietary heptad platform djs lpar antagonist antibody currently preclinical studies treatment idiopathic pulmonary fibrosis fibrotic diseases heptad platform potential novel approach antibody discovery specific capabilities targeting transmembrane protein targets aggregate purchase price million comprised million upfront cash payment million acquisition date fair value contingent consideration liabilities abbvie may owe million future payments upon achievement certain development milestones transaction accounted business combination using acquisition method accounting acquisition date abbvie acquired million intangible assets inprocess research development million intangible assets developed product rights million deferred tax liabilities assets liabilities assumed insignificant acquisition resulted recognition million goodwill deductible tax purposes acquisition soliton inc december abbvie completed previously announced acquisition soliton inc soliton soliton 's resonic rapid acoustic pulse device us food drug administration fda k clearance longterm improvement appearance cellulite one year transaction accounted business combination using acquisition method accounting total consideration transferred allocated purchase price consisted cash consideration million paid holders soliton common stock equitybased awards warrants transaction date abbvie acquired million intangible assets developed product rights assumed deferred tax liabilities totaling million assets liabilities insignificant acquisition resulted recognition million goodwill deductible tax purposes acquisition luminera october abbvie entered agreement luminera privately held aesthetics company based israel acquire luminera 's full dermal filler portfolio rd pipeline including harmonyca dermal filler intended facial soft tissue augmentation aggregate accounting purchase price million comprised million upfront cash payment million acquisition date fair value contingent consideration liabilities abbvie may owe million future payments upon achievement certain commercial milestones agreement accounted business combination using acquisition method accounting acquisition date abbvie acquired million intangible assets inprocess research development million intangible assets developed product rights assets liabilities assumed insignificant acquisition resulted recognition million goodwill deductible tax purposes acquisition allergan may abbvie completed acquisition outstanding equity interests allergan cash stock transaction allergan global pharmaceutical leader focused developing manufacturing commercializing branded pharmaceutical device biologic surgical regenerative medicine products patients around world combination created diverse entity leadership positions across immunology hematologic oncology aesthetics neuroscience eye care abbvie 's existing product portfolio pipeline enhanced numerous allergan assets allergan 's product portfolio benefits abbvie 's commercial strength expertise international infrastructure terms acquisition ordinary share allergan common stock converted right receive cash ii share abbvie common stock total consideration acquisition allergan summarized follows millions cash consideration paid allergan shareholders fair value abbvie common stock issued allergan shareholders b fair value abbvie equity awards issued allergan equity award holders c total consideration represents cash consideration transferred per outstanding allergan ordinary share based million allergan ordinary shares outstanding closing b represents acquisition date fair value million shares abbvie common stock issued allergan shareholders based exchange ratio abbvie shares outstanding allergan ordinary share may closing price per share c represents preacquisition service portion fair value million abbvie stock options million rsus issued allergan equity award holders acquisition allergan accounted business combination using acquisition method accounting acquisition method requires among things assets acquired liabilities assumed business combination recognized fair values acquisition date valuation assets acquired liabilities assumed finalized second quarter measurement period adjustments preliminary purchase price allocation included increase intangible assets million ii increase deferred income tax liabilities million iii individually insignificant adjustments net increase identifiable net assets million iv corresponding decrease goodwill million measurement period adjustments primarily resulted completion valuation certain license agreement intangible assets based facts circumstances existed acquisition date result intervening events subsequent date adjustments significant impact abbvie 's results operations would significant impact prior period results adjustments made acquisition date following table summarizes final fair value assets acquired liabilities assumed acquisition date millions assets acquired liabilities assumed cash equivalents shortterm investments accounts receivable inventories prepaid expenses current assets investments property equipment intangible assets definitelived intangible assets inprocess research development noncurrent assets shortterm borrowings current portion longterm debt finance lease obligations accounts payable accrued liabilities longterm debt finance lease obligations deferred income taxes longterm liabilities total identifiable net assets goodwill total assets acquired liabilities assumed fair value stepup adjustment inventories billion amortized cost products sold inventory sold customers fully amortized december intangible assets relate billion definitelived intangible assets billion iprd acquired definitelived intangible assets consist developed product rights license agreements amortized weightedaverage estimated useful life approximately twelve years using estimated pattern economic benefit estimated fair values identifiable intangible assets determined using income approach valuation technique provides estimate fair value asset based market participant expectations cash flows asset would generate remaining useful life significant assumptions inherent development asset valuations include estimated net cash flows year asset product appropriate discount rate necessary measure risk inherent future cash flow stream life cycle asset potential regulatory commercial success risk competitive trends impacting asset cash flow stream well factors form kthe fair value longterm debt determined quoted market prices acquisition date total purchase price adjustment billion amortized reduction interest expense net lives related debt goodwill calculated excess consideration transferred net assets recognized represents future economic benefits arising assets acquired could individually identified separately recognized specifically goodwill recognized acquisition allergan represents value additional growth platforms expanded revenue base well anticipated operational synergies cost savings creation single combined global organization goodwill deductible tax purposes following acquisition date operating results allergan included consolidated financial statements period acquisition date december net revenues attributable allergan billion operating losses attributable allergan billion inclusive billion intangible asset amortization billion inventory fair value stepup amortization acquisitionrelated expenses comprised primarily regulatory financial advisory legal fees totaled million year ended december included sga expenses consolidated statements earnings fourth quarter abbvie recovered certain acquisitionrelated regulatory fees totaling million recorded reduction sga expenses consolidated statement earnings year ended december pro forma financial information following table presents unaudited pro forma combined results abbvie allergan acquisition allergan occurred january years ended december millions net revenues net earnings unaudited pro forma combined financial information prepared using acquisition method accounting based historical financial information abbvie allergan order reflect occurrence acquisition january required unaudited pro forma financial information includes adjustments reflect incremental amortization expense incurred based final fair values identifiable intangible assets acquired incremental cost products sold related fair value adjustments associated acquisition date inventory additional interest expense associated issuance debt finance acquisition reclassification acquisitionrelated costs incurred year ended december year ended december unaudited pro forma financial information necessarily indicative consolidated results operations would acquisition completed january addition unaudited pro forma financial information projection future results operations combined company reflect expected realization synergies cost savings associated acquisition licensing acquisitions activity cash outflows related acquisitions investments totaled million billion billion abbvie recorded acquired iprd milestones expense million billion billion significant arrangements impacting require contingent milestone payments summarized syndesi therapeutics sa february abbvie acquired syndesi therapeutics sa portfolio novel modulators synaptic vesicle protein including lead molecule sdi accounted transaction asset acquisition sdi small molecule currently phase b studies evaluated target nerve terminals enhance synaptic efficiency terms agreement abbvie made upfront payment million recorded acquired iprd milestones expense consolidated statement earnings first quarter agreement also includes additional future payments million upon achievement certain development regulatory commercial milestones juvise pharmaceuticals june abbvie laboratories juvise pharmaceuticals juvise entered asset purchase agreement juvise acquired worldwide commercial rights mature brand pylera used treatment peptic ulcers infection bacterium helicobacter pylori transaction accounted sale asset upon completion transaction abbvie received net cash proceeds million recognized pretax gain million recorded operating income consolidated statement earnings second quarter calico life sciences llc july abbvie calico life sciences llc calico entered extension collaboration discover develop bring market new therapies patients agerelated diseases including neurodegeneration cancer second collaboration extension builds partnership established extended terms agreement abbvie calico contribute additional million term extended additional three years abbvies contribution payable two equal installments beginning calico responsible research early development advance collaboration projects phase following completion phase studies abbvie option exclusively license collaboration compounds upon exercise abbvie would responsible latestage development commercial activities collaboration costs profits shared equally parties post option exercise third quarter abbvie recorded million operating expense consolidated statement earnings related commitments agreement teneoone tnbb september abbvie acquired teneoone affiliate teneobio inc tnbb bcmatargeting immunotherapeutic potential treatment relapsed refractory multiple myeloma rr mm february abbvie teneoone entered strategic transaction develop commercialize tnb b bispecific antibody simultaneously targets bcma cd designed direct body 's immune system target kill bcmaexpressing tumor cells abbvie exercised exclusive right acquire teneoone tnbb based interim analysis ongoing phase study accounted transaction asset acquisition terms agreement abbvie made exercise payment million recorded acquired iprd milestones expense consolidated statement earnings third quarter agreement also included additional payments million upon achievement certain development regulatory commercial milestones regenxbio inc september abbvie regenxbio inc regenxbio entered collaboration develop commercialize rgx investigational gene therapy wet agerelated macular degeneration diabetic retinopathy chronic retinal diseases collaboration provides abbvie exclusive global license develop commercialize rgx regenxbio responsible completion ongoing trials abbvie regenxbio collaborate share costs additional trials abbvie lead clinical development commercialization rgx globally regenxbio abbvie share equally pretax profits net revenues rgx us abbvie pay regenxbio tiered royalties net revenues outside us upon closing fourth quarter abbvie made upfront payment million exclusively license rgx recorded acquired iprd milestones expense consolidated statement earnings year ended december agreement also included additional payments billion upon achievement certain development regulatory commercial milestones imab biopharma september abbvie imab biopharma imab entered collaboration agreement development commercialization lemzoparlimab anticd monoclonal antibody internally discovered developed imab treatment multiple cancers companies collaborate design conduct global clinical trials evaluate lemzoparlimab collaboration provides abbvie exclusive global license excluding greater china develop commercialize lemzoparlimab companies share manufacturing responsibilities abbvie primary manufacturer global supply agreement also allows potential collaboration future cdrelated therapeutic agents subject licenses explore 's related programs respective territories terms arrangement include initial upfront payment million exclusively license lemzoparlimab along milestone payment million based phase results total million recorded acquired iprd milestones expense consolidated statement earnings fourth quarter regulatory approval form ktransaction addition imab eligible receive billion upon achievement certain clinical development regulatory commercial milestones abbvie pay tiered royalties lowtomid teen percentages global net revenues outside greater china genmab june abbvie genmab genmab entered collaboration agreement jointly develop commercialize three genmab 's earlystage investigational bispecific antibody therapeutics entered discovery research collaboration future differentiated antibody therapeutics treatment cancer terms agreement genmab granted abbvie exclusive license epcoritamab duobodycdxcd duohexabodycd duobodycdxt programs epcoritamab companies share commercial responsibilities us japan abbvie responsible global commercialization genmab record net revenues us japan parties share equally pretax profits sales genmab receive tiered royalties remaining global sales discovery research partnership genmab conduct phase studies programs abbvie retains right optin program development abbvie made upfront payment million recorded acquired iprd milestones expense consolidated statement earnings abbvie could make additional payments billion upon achievement certain development regulatory commercial milestones programs arrangements addition significant arrangements described abbvie entered several arrangements resulting charges related upfront payments million million million connection individually insignificant earlystage arrangements entered abbvie could make additional payments billion upon achievement certain development regulatory commercial milestones acquired iprd milestones expense also included development milestones million million million note collaborations company ongoing transactions entities collaboration agreements following represent significant collaboration agreements impacting collaboration janssen biotech inc december pharmacyclics whollyowned subsidiary abbvie entered worldwide collaboration license agreement janssen biotech inc affiliates janssen one janssen pharmaceutical companies johnson johnson joint development commercialization imbruvica novel orally active selective covalent inhibitor bruton 's tyrosine kinase certain compounds structurally related imbruvica oncology indications excluding immune inflammatory mediated diseases conditions psychiatric psychological diseases conditions united states outside united states collaboration provides janssen exclusive license commercialize imbruvica outside united states coexclusively abbvie united states parties responsible development manufacturing marketing products generated result collaboration collaboration set duration specific expiration date provides potential future development regulatory approval milestone payments million abbvie collaboration also includes cost sharing arrangement associated collaboration activities except certain cases janssen responsible approximately collaboration development costs abbvie responsible remaining collaboration development costs united states parties coexclusive rights commercialize products however abbvie principal endcustomer product sales abbvie janssen share pretax profits losses equally commercialization products sales imbruvica included abbvie 's net revenues janssen 's share profits included abbvie 's cost products sold costs incurred collaboration reported respective expense line items net janssen 's share outside united states janssen responsible exclusive rights commercialize imbruvica abbvie janssen share pretax profits losses equally commercialization products abbvie 's share profits included abbvie 's net revenues costs incurred collaboration reported respective expense line items net janssen 's share following table shows profit cost sharing relationship janssen abbvie years ended december millions united states janssen 's share profits included cost products sold international abbvie 's share profits included net revenues global abbvie 's share costs included respective line items abbvies receivable janssen included accounts receivable net million december million december abbvies payable janssen included accounts payable accrued liabilities million december million december collaboration genentech inc abbvie genentech inc genentech member roche group parties collaboration license agreement executed jointly research develop commercialize human therapeutic products containing bcl inhibitors certain compound inhibitors includes venclexta bcl inhibitor used treat certain hematological malignancies abbvie shares equally genentech pretax profits losses development commercialization venclexta united states abbvie pays royalties venclexta net revenues outside united states abbvie manufactures distributes venclexta globally principal endcustomer product sales sales venclexta included abbvie 's net revenues genentech 's share united states profits included abbvie 's cost products sold abbvie records sales marketing costs associated united states collaboration part sga expenses global development costs part rd expenses net genentechs share royalties paid venclexta revenues outside united states also included abbvies cost products sold following table shows profit cost sharing relationship genentech abbvie years ended december millions genentech 's share profits including royalties included cost products sold abbvie 's share sales marketing costs us collaboration included sga abbvie 's share development costs included rd form knote goodwill intangible assets goodwill following table summarizes changes carrying amount goodwill millions balance december additionsa measurement period adjustmentsb foreign currency translation adjustments balance december additionsc foreign currency translation adjustments balance december goodwill additions related acquisition soliton fourth quarter see note b measurement period adjustments recorded related acquisition allergan see note c goodwill additions related acquisition djs fourth quarter see note company performs annual goodwill impairment assessment third quarter earlier impairment indicators exist december accumulated goodwill impairment losses intangible assets net following table summarizes intangible assets gross net gross net december carrying accumulated carrying carrying accumulated carrying millions amount amortization amount amount amortization amount definitelived intangible assets developed product rights license agreements total definitelived intangible assets indefinitelived intangible assets total intangible assets net definitelived intangible assets september company made strategic decision reduce ongoing sales marketing investment related vuity onmarket product treat presbyopia strategic decision contributed significant decrease estimated future cash flows product represented triggering event required company evaluate underlying definite livedintangible asset impairment company utilized discounted cash flow analysis estimate fair value intangible asset resulting full impairment gross net carrying amount based revised cash flows company recorded pretax impairment charge million cost products sold consolidated statement earnings third quarter definitelived intangible assets amortized estimated useful lives range years average years developed product rights years license agreements amortization expense billion billion billion included cost products sold consolidated statements earnings anticipated annual amortization expense definitelived intangible assets recorded december follows billions anticipated annual amortization expense indefinitelived intangible assets indefinitelived intangible assets represent acquired iprd associated products yet received regulatory approval indefinitelived intangible assets december primarily relate acquisitions allergan djs company performs annual impairment assessment indefinitelived intangible assets third quarter earlier impairment indicators exist note integration restructuring plans allergan integration plan following closing allergan acquisition abbvie implemented integration plan designed reduce costs integrate optimize combined organization incurred total cumulative charges billion costs consisted severance employee benefit costs cash severance noncash severance including accelerated equity award compensation expense retention termination benefits integration expenses following table summarizes charges benefits associated allergan acquisition integration plan severance employee benefits integration year ended december millions cost products sold research development selling general administrative total charges benefits following table summarizes cash activity recorded liability associated integration plan severance year ended december millions employee benefits integration charges payments adjustments accrued balance december charges payments adjustments accrued balance december charges benefits payments adjustments accrued balance december restructuring abbvie continuously evaluates operations identify opportunities optimize manufacturing rd operations commercial infrastructure administrative costs respond changes business environment result abbvie management periodically approves individual restructuring plans achieve objectives plans individually significant restructuring charges recorded million million million primarily related employee severance contractual obligations charges recorded cost products sold rd expense sga expenses consolidated statements earnings based classification affected employees operations form kthe following table summarizes cash activity restructuring reserve millions accrued balance december restructuring charges payments adjustments accrued balance december restructuring charges payments adjustments accrued balance december restructuring charges payments adjustments accrued balance december note leases abbvie 's lease portfolio primarily consists real estate properties vehicles equipment following table summarizes amounts location operating finance leases consolidated balance sheets december millions balance sheet caption assets operating assets finance property equipment net total lease assets liabilities operating current accounts payable accrued liabilities noncurrent longterm liabilities finance current current portion longterm debt finance lease obligations noncurrent longterm debt finance lease obligations total lease liabilities following table summarizes lease costs recognized consolidated statements earnings years ended december millions operating lease cost shortterm lease cost variable lease cost total lease cost december company entered agreement sublease portion madison new jersey office space end original lease maturity result agreement company recognized impairment loss rightofuse asset million wroteoff related leasehold improvements million losses recorded sga expense consolidated statements earnings year ended december company used discounted cash flows method value rightofuse asset determine impairment amount sublease income finance lease costs insignificant following table presents weightedaverage remaining lease term weightedaverage discount rate operating finance leases years ended december weightedaverage remaining lease term years operating finance weightedaverage discount rate operating finance following table presents supplementary cash flow information regarding company 's leases years ended december millions cash paid amounts included measurement lease liabilities operating cash flows operating leases rightofuse assets obtained exchange new operating lease liabilities finance lease cash flows insignificant rightofuse assets obtained exchange new operating lease liabilities december included million rightofuse assets acquired allergan acquisition following table summarizes future maturities abbvie 's operating finance lease liabilities december operating finance millions leases leases total thereafter total lease payments less interest present value lease liabilities lease payments recognized part lease liabilities optional renewal periods insignificant form knote debt credit facilities commitments contingencies following table summarizes longterm debt effective effective december dollars millions interest rate interest rate aggregate notes due senior notes due senior notes due floating rate term loans due senior euro notes due principal senior notes due senior notes due senior euro notes due principal senior notes due senior euro notes due principal senior notes due senior notes due floating rate term loans due floating rate term loans due senior notes due senior notes due senior euro notes due principal senior notes due senior euro notes due principal senior euro notes due principal senior notes due senior euro notes due principal senior euro notes due principal senior notes due senior notes due senior notes due senior notes due senior notes due senior notes due senior notes due senior notes due senior notes due senior notes due senior notes due senior notes due fair value hedges unamortized bond discounts unamortized deferred financing costs unamortized bond premiums b total longterm debt finance lease obligations current portion noncurrent portion excludes effect related interest rate swaps b represents unamortized purchase price adjustments allergan debt senior notes floating rate term loans redeemable prior maturity redemption price equal principal amount plus makewhole premium abbvie may redeem debt securities par generally one six months prior maturity december company compliance senior note covenants term loan covenants maturities longterm debt years ending december millions thereafter total obligations commitments fair value hedges unamortized bond premiumsdiscounts deferred financing costs finance lease obligations total longterm debt finance lease obligations repayment issuance longterm debt company repaid billion aggregate principal amount senior notes billion aggregate principal amount senior notes billion aggregate principal amount senior notes repayments made exercising terms notes ranging day early redemptions principal amount quarter ended december company also paid billion aggregate principal amount senior notes billion aggregate principal amount senior notes million aggregate principal amount floating rate senior notes maturity additionally company refinanced billion floating rate fiveyear term loan part refinancing company repaid existing billion term loan due may borrowed billion new term loan lower floating rate significant terms loan including maturity date remained unchanged refinancing subsequent december company repaid billion floating rate threeyear term loan scheduled mature may company repaid billion aggregate principal amount senior notes million aggregate principal amount senior euro notes billion aggregate principal amount senior notes repayments made exercising terms notes ranging day early redemptions principal amounts company also repaid billion aggregate principal amount senior notes billion aggregate principal amount senior notes billion aggregate principal amount floating rate senior notes maturity additionally company refinanced billion floating rate threeyear term loan part refinancing company repaid existing billion term loan due may borrowed billion new term loan lower floating rate significant terms loan including maturity date remained unchanged refinancing shortterm borrowings commercial paper borrowings outstanding december december commercial paper borrowings issued commercial paper borrowings issued weightedaverage interest rate abbvie currently billion fiveyear revolving credit facility matures august credit facility enables company borrow funds unsecured basis variable interest rates contains various covenants company compliance december commitment fees abbvie 's revolving credit facilities insignificant amounts outstanding company 's credit facilities december december contingencies guarantees connection separation abbvie indemnified abbott liabilities resulting operation abbvie 's business income tax liabilities respect periods prior distribution date liabilities agreed abbvie abbott abbvie material exposures balance sheet arrangements specialpurpose entities ordinary course business abbvie periodically entered thirdparty agreements assignment product rights resulted abbvie becoming secondarily liable obligations abbvie previously primarily liable based upon past experience likelihood payments agreements remote form knote financial instruments fair value measures risk management policy company exposed foreign currency exchange rate interest rate risks related business operations abbvie 's hedging policy attempts manage risks acceptable level based company 's judgment appropriate tradeoff risk opportunity costs company uses derivative nonderivative instruments reduce exposure foreign currency exchange rates abbvie also periodically enters interest rate swaps company agrees exchange specified intervals difference fixed floating interest amounts calculated reference agreedupon notional amount derivative instruments used trading purposes manage exposure changes interest rates investment securities none company 's outstanding derivative instruments contain credit risk related contingent features collateral generally required financial instruments various abbvie foreign subsidiaries enter foreign currency forward exchange contracts manage exposures changes foreign exchange rates anticipated intercompany transactions denominated currency functional currency local entity contracts notional amounts totaling billion december billion december designated cash flow hedges recorded fair value durations forward exchange contracts generally less months accumulated gains losses december reclassified aoci included cost products sold time products sold generally exceeding six months date settlement company entered treasury rate lock agreements notional amounts totaling billion hedge exposure variability future cash flows resulting changes interest rates related issuance longterm debt connection acquisition allergan treasury rate lock agreements designated cash flow hedges recorded fair value agreements net settled upon issuance senior notes resulting net gain recognized comprehensive income gain reclassified interest expense net term related debt company party interest rate swap contracts designated cash flow hedges matured november notional amount million december effect hedge contracts change floatingrate interest obligation fixed rate portion floating rate debt realized unrealized gains losses included aoci reclassified interest expense net lives floatingrate debt company also enters foreign currency forward exchange contracts manage exposure foreign currency denominated trade payables receivables intercompany loans contracts designated hedges recorded fair value resulting gains losses reflected net foreign exchange loss consolidated statements earnings generally offset losses gains foreign currency exposure managed contracts notional amounts totaling billion december billion december company also uses foreign currency forward exchange contracts foreign currency denominated debt hedge net investments certain foreign subsidiaries affiliates company aggregate principal amount senior euro notes designated net investment hedges billion december december addition company foreign currency forward exchange contracts designated net investment hedges notional amounts totaling billion sek billion cad million chf million december billion december company uses spot method assessing hedge effectiveness derivative instruments designated net investment hedges realized unrealized gains losses hedges included aoci initial fair value hedge components excluded assessment effectiveness recognized interest expense net life hedging instrument company party interest rate swap contracts designated fair value hedges notional amounts totaling billion december december effect hedge contracts change fixedrate interest obligation floating rate portion debt abbvie records contracts fair value adjusts carrying amount fixedrate debt offsetting amount amounts excluded assessment effectiveness cash flow hedges fair value hedges following table summarizes amounts location abbvie 's derivative instruments consolidated balance sheets fair value fair value derivatives asset position derivatives liability position balance sheet balance sheet december millions caption caption foreign currency forward exchange contracts prepaid expenses accounts payable designated cash flow hedges accrued liabilities longterm designated cash flow hedges assets liabilities designated net investment prepaid expenses accounts payable hedges accrued liabilities designated net investment longterm hedges assets liabilities prepaid expenses accounts payable designated hedges accrued liabilities interest rate swap contracts prepaid expenses accounts payable designated cash flow hedges accrued liabilities prepaid expenses accounts payable designated fair value hedges accrued liabilities longterm designated fair value hedges assets liabilities total derivatives certain derivatives subject netting arrangements company 's counterparties company offset derivative assets liabilities within consolidated balance sheets following table presents pretax amounts gains losses derivative instruments recognized comprehensive income years ended december millions foreign currency forward exchange contracts designated cash flow hedges designated net investment hedges interest rate swap contracts designated cash flow hedges assuming market rates remain constant contract maturities company expects reclassify pretax gains million cost products sold foreign currency cash flow hedges pretax gains million interest expense net treasury rate lock agreement cash flow hedges next months related abbvies nonderivative foreign currency denominated debt designated net investment hedges company recognized comprehensive income pretax gains million pretax gains million pretax losses million form kthe following table summarizes pretax amounts location derivative instrument net gains losses recognized consolidated statements earnings including net gains losses reclassified aoci net earnings see note amount net gains losses reclassified aoci years ended december millions statement earnings caption foreign currency forward exchange contracts designated cash flow hedges cost products sold designated net investment hedges interest expense net designated hedges net foreign exchange loss treasury rate lock agreements designated cash flow hedges interest expense net interest rate swap contracts designated cash flow hedges interest expense net designated fair value hedges interest expense net debt designated hedged item fair value hedges interest expense net fair value measures fair value hierarchy consists following three levels level valuations based unadjusted quoted prices active markets identical assets company ability access level valuations based quoted prices similar instruments active markets quoted prices identical similar instruments markets active modelbased valuations significant inputs observable market level valuations using significant inputs unobservable market include use judgment company 's management assumptions market participants would use pricing asset liability following table summarizes bases used measure certain assets liabilities carried fair value recurring basis consolidated balance sheet december basis fair value measurement quoted prices significant active markets observable significant identical assets inputs unobservable inputs millions total level level level assets cash equivalents money market funds time deposits debt securities equity securities foreign currency contracts total assets liabilities interest rate swap contracts foreign currency contracts contingent consideration total liabilities following table summarizes bases used measure certain assets liabilities carried fair value recurring basis consolidated balance sheet december basis fair value measurement quoted prices significant active markets identical observable significant assets inputs unobservable inputs millions total level level level assets cash equivalents money market funds time deposits debt securities equity securities interest rate swap contracts foreign currency contracts total assets liabilities interest rate swap contracts foreign currency contracts contingent consideration total liabilities money market funds time deposits valued using relevant observable market inputs including quoted prices similar assets interest rate curves equity securities primarily consist investments fair values determined using published market prices per unit multiplied number units held without consideration transaction costs derivatives entered company valued using observable market inputs including published interest rate curves forward spot prices foreign currencies fair value measurements contingent consideration liabilities determined based significant unobservable inputs including discount rate estimated probabilities timing achieving specified development regulatory commercial milestones estimated amount future sales acquired products potential contingent consideration payments estimated applying probabilityweighted expected payment model contingent milestone payments monte carlo simulation model contingent royalty payments discounted present value changes fair value contingent consideration liabilities result changes one number inputs including discount rates probabilities achieving milestones time required achieve milestones form kand estimated future sales significant judgment employed determining appropriateness certain inputs changes inputs described could material impact company 's financial position results operations given period fair value company 's contingent consideration liabilities calculated using following significant unobservable inputs years ended december millions range weighted averagea range weighted averagea discount rate probability payment unachieved milestones probability payment royalties indicationb projected year payments unobservable inputs weighted relative fair value contingent consideration liabilities b excluding approved indications estimated probability payment december ranged december transfers assets liabilities level fair value hierarchy following table presents changes fair value contingent consideration liabilities measured using level inputs years ended december millions beginning balance additionsa change fair value recognized net earnings payments ending balance additions year ended december represent contingent consideration liabilities assumed djs acquisition additions year ended december represent contingent consideration liabilities assumed allergan luminera acquisitions see note change fair value recognized net earnings recorded expense net consolidated statements earnings included charges billion billion billion change fair value reflected higher estimated skyrizi sales driven stronger market share uptake passage time partially offset higher discount rates change fair value reflected higher estimated skyrizi sales driven stronger market share uptake favorable clinical trial results passage time partially offset higher discount rates change fair value reflected higher estimated skyrizi sales driven stronger market share uptake lower discount rates passage time favorable clinical trial results certain financial instruments carried historical cost basis fair value book values approximate fair values bases used measure approximate fair values certain financial instruments december shown table basis fair value measurement quoted prices active markets identical significant significant approximate fair assets observable inputs unobservable inputs millions book value values level level level liabilities shortterm borrowings current portion longterm debt finance lease obligations excluding fair value hedges longterm debt finance lease obligations excluding fair value hedges total liabilities book values approximate fair values bases used measure approximate fair values certain financial instruments december shown table basis fair value measurement quoted prices active markets identical significant significant approximate fair assets observable inputs unobservable inputs millions book value values level level level liabilities shortterm borrowings current portion longterm debt finance lease obligations excluding fair value hedges longterm debt finance lease obligations excluding fair value hedges total liabilities abbvie also holds investments equity securities readily determinable fair values company records investments cost remeasures fair value based certain observable price changes impairment events occur carrying amount investments million december million december significant cumulative upward downward adjustments recorded investments december concentrations risk total net accounts receivable three us wholesalers accounted december december substantially abbvie 's pharmaceutical product net revenues united states three wholesalers humira adalimumab abbvie 's single largest product accounted approximately abbvie 's total net revenues form knote postemployment benefits abbvie sponsors various pension postemployment benefit plans including defined benefit defined contribution termination indemnity plans cover employees worldwide addition abbvie provides medical benefits primarily eligible retirees united states puerto rico postretirement benefit plans net obligations plans reflected consolidated balance sheets december following table summarizes benefit plan information global abbviesponsored defined benefit postemployment plans defined benefit plans postemployment plans years ended december millions projected benefit obligations beginning period service cost interest cost employee contributions amendments actuarial gain loss benefits paid primarily foreign currency translation adjustments end period fair value plan assets beginning period actual return plan assets company contributions employee contributions benefits paid primarily foreign currency translation adjustments end period funded status end period amounts recognized consolidated balance sheets assets accounts payable accrued liabilities longterm liabilities net obligation actuarial loss net prior service cost credit accumulated comprehensive loss related international defined benefit plans projected benefit obligations table included billion december billion december plans reflected table accumulated benefit obligations billion december billion december actuarial gain billion qualified pension plans actuarial gain million postemployment plans primarily driven increase discount rate actuarial gain million qualified pension plans actuarial loss million post employment plans primarily driven increase assumed discount rate offset change demographic assumptions information pension plans accumulated benefit obligation excess plan assets december millions accumulated benefit obligation fair value plan assets information pension plans projected benefit obligation excess plan assets december millions projected benefit obligation fair value plan assets abbvie 's us pension plan modified close plan new entrants effective january addition change abbvie 's us retiree health benefit plan approved communicated employees retirees october beginning medicareeligible retirees medicare eligible dependents choose health care coverage insurance providers private medicare exchange abbvie continue provide financial support medicareeligible retirees change us retiree health benefit plan decreased abbvie 's postemployment benefit obligation increased abbvie 's unrecognized prior service credit december million form kamounts recognized comprehensive income following table summarizes pretax losses gains included comprehensive income years ended december millions defined benefit plans actuarial loss gain amortization prior service cost amortization actuarial loss foreign exchange loss gain total loss gain postemployment plans actuarial loss gain prior service credit amortization prior service credit amortization actuarial loss total loss gain net periodic benefit cost years ended december millions defined benefit plans service cost interest cost expected return plan assets amortization prior service cost amortization actuarial loss net periodic benefit cost postemployment plans service cost interest cost amortization prior service credit amortization actuarial loss net periodic benefit cost components net periodic benefit cost service cost included expense net consolidated statements earnings weightedaverage assumptions used determining benefit obligations measurement date december defined benefit plans discount rate rate compensation increases cash balance interest crediting rate postemployment plans discount rate assumptions used calculating december measurement date benefit obligations used calculation net periodic benefit cost weightedaverage assumptions used determining net periodic benefit cost years ended december defined benefit plans discount rate determining service cost discount rate determining interest cost expected longterm rate return plan assets expected rate change compensation cash balance interest crediting rate postemployment plans discount rate determining service cost discount rate determining interest cost december postretirement health care obligations remeasurement company assumed pre post annual rate increase per capita cost covered health care benefits pre rate assumed decrease gradually post remain level thereafter purposes measuring postretirement health care costs company assumed pre post annual rate increase per capita cost covered health care benefits pre rate assumed decrease gradually post remain level thereafter form kdefined benefit pension plan assets basis fair value measurement quoted prices active markets significant significant unobservable identical assets observable inputs inputs december millions level level level equities us large capa us mid capb internationalc fixed income securities us government securitiesd corporate debt instrumentsd nonus government securitiesd otherd absolute return fundse real assets otherf total total assets measured nav fair value plan assets basis fair value measurement quoted prices active markets significant significant unobservable identical assets observable inputs inputs december millions level level level equities us large capa us mid capb internationalc fixed income securities us government securitiesd corporate debt instrumentsd nonus government securitiesd otherd absolute return fundse real assets otherf total total assets measured nav fair value plan assets mix index funds actively managed equity accounts benchmarked various large cap indices b mix index funds actively managed equity accounts benchmarked various mid cap indices c mix index funds actively managed equity accounts benchmarked various nonus equity indices developed emerging markets securities held actively managed accounts index funds mutual funds e primarily funds global mandates flexibility allocate capital broadly across wide range asset classes strategies including limited equities fixed income commodities financial futures currencies securities objectives outperform agreed upon benchmarks specific return volatility targets f investments cash cash equivalents equities registered investment companies quoted prices valued published market prices fixed income securities valued using significant observable inputs quoted prices obtained independent financial service industryrecognized vendors investments held pooled investment funds common collective trusts limited partnerships valued net asset value nav practical expedient estimate fair value nav provided fund administrator based value underlying assets owned fund minus liabilities investment mix equity securities fixed income asset allocation strategies based upon achieving desired return balancing higher return volatile equity securities lower return less volatile fixed income securities investment allocations established plan generally made across range markets industry sectors capitalization sizes case fixed income securities maturities credit quality target investment allocation abbvie pension plan equity securities fixed income securities asset allocation strategies holdings known significant concentrations risk plan assets abbvie pension plan plans expected return plan assets assumption plan based management 's expectations longterm average rates return achieved underlying investment portfolio establishing assumption management considers historical expected returns asset classes plans invested well current economic capital market conditions expected benefit payments following table summarizes total benefit payments expected paid plan participants including payments funded plan company assets defined years ending december millions benefit plans postemployment plans defined contribution plan abbvie maintains defined contribution savings plans benefit eligible employees expense recognized plans million million million abbvie provides certain postemployment benefits primarily salary continuation arrangements qualifying employees accrues related cost service lives employees note equity stockbased compensation may stockholders company approved abbvie amended restated incentive stock program amended plan amends restates abbvie incentive stock program isp abbvie grants stockbased awards eligible employees pursuant amended plan provides several different forms benefits including nonqualified stock options rsus various performancebased awards amended plan total million shares abbvie common stock reserved issuance awards abbvie employees form kabbvie measures compensation expense stockbased awards based grant date fair value awards estimated number awards expected vest forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates compensation cost stockbased awards amortized service period could shorter vesting period employee retirement eligible retirement eligible employees generally age older least years service stockbased compensation expense principally related awards issued pursuant isp amended plan summarized follows years ended december millions cost products sold research development selling general administrative pretax compensation expense tax benefit aftertax compensation expense realized excess tax benefits associated stockbased compensation totaled million million million stock options stock options awarded employees typically contractual term years generally vest onethird increments threeyear period exercise price equal least market value date grant fair value determined using blackscholes model weightedaverage grantdate fair values stock options granted connection allergan acquisition second quarter abbvie issued million stock options holders allergan options result conversion options options fairvalued using lattice valuation model refer note additional information regarding allergan acquisition following table summarizes abbvie stock option activity weightedaverage weighted average remaining aggregate intrinsic options thousands aggregate intrinsic value millions options exercise price life years value outstanding december granted exercised lapsed forfeited outstanding december exercisable december total intrinsic value options exercised million million million total fair value options vested million december million unrecognized compensation cost related stock options expected recognized expense approximately next two years rsus performance shares rsus awarded employees senior executives key employees generally vest ratable increments three fouryear period recipients rsus entitled receive dividend equivalents dividends declared paid rsu vesting period majority equity awards abbvie grants senior executives key employees performancebased equity awards granted senior executives key employees consist combination performancevested rsus performance shares well nonqualified stock options described performancevested rsus potential vest onethird increments threeyear performance period may earned based abbvies return invested capital roic performance relative defined peer group pharmaceutical biotech life science companies recipient may receive one share abbvie common stock vested award performance shares potential vest threeyear performance period may earned based abbvies eps achievement abbvies total stockholder return tsr market condition relative defined peer group pharmaceutical biotech life sciences companies dividend equivalents performancevested rsus performance shares accrue performance period payable vesting extent shares earned weightedaverage grantdate fair value rsus performance shares generally determined based number sharesunits granted quoted price abbvies common stock date grant weightedaverage grantdate fair values performance shares tsr market condition determined using monte carlo simulation model following table summarizes abbvie rsu performance share activity weightedaverage grant share units thousands share units date fair value outstanding december granted vested forfeited outstanding december fair market value rsus performance shares applicable vested billion million million connection allergan acquisition second quarter abbvie issued million rsus holders allergan equity awards based conversion factor described transaction agreement refer note additional information regarding allergan acquisition december million unrecognized compensation cost related rsus performance shares expected recognized expense approximately next two years cash dividends cash dividends declared per common share totaled following table summarizes quarterly cash dividends declared date payment dividend date payment dividend date payment dividend declared date per share declared date per share declared date per share stock repurchase program company 's stock repurchase authorization permits purchases abbvie shares time time openmarket private transactions managements discretion program time limit discontinued time shares repurchased programs recorded acquisition cost including related expenses available general corporate purposes abbvie repurchased million shares billion million shares million million shares million abbvie 's remaining stock repurchase authorization billion december february abbvie 's board directors authorized billion increase existing stock repurchase authorization form kaccumulated comprehensive loss following table summarizes changes component accumulated comprehensive loss net tax pension foreign currency net investment postemployment cash flow millions brackets denote losses translation adjustments hedging activities benefits hedging activities total balance december comprehensive income loss reclassifications net losses gains reclassified accumulated comprehensive loss net currentperiod comprehensive income loss balance december comprehensive income loss reclassifications net losses gains reclassified accumulated comprehensive loss net currentperiod comprehensive income loss balance december comprehensive income loss reclassifications net losses gains reclassified accumulated comprehensive loss net currentperiod comprehensive income loss balance december comprehensive income included pension postemployment benefit plan gains billion primarily due actuarial gains driven higher discount rates partially offset losses plan assets comprehensive income also included foreign currency translation adjustments totaling losses million principally due impact weakening euro translation companys eurodenominated assets offsetting impact net investment hedging activities totaling gains million comprehensive income included foreign currency translation adjustments totaling losses billion principally due impact weakening euro translation company 's eurodenominated assets offsetting impact net investment hedging activities totaling gains million comprehensive income included foreign currency translation adjustments totaling gains billion principally due impact strengthening euro translation company 's euro denominated assets offsetting impact net investment hedging activities totaling losses million table presents impact abbvie 's consolidated statements earnings significant amounts reclassified component accumulated comprehensive loss years ended december millions brackets denote gains net investment hedging activities gains derivative amount excluded effectiveness testinga tax expense total reclassifications net tax pension postemployment benefits amortization actuarial losses otherb tax benefit total reclassifications net tax cash flow hedging activities losses gains foreign currency forward exchange contractsc gains treasury rate lock agreementsa losses interest rate swap contractsa tax expense benefit total reclassifications net tax amounts included interest expense net see note b amounts included computation net periodic benefit cost see note c amounts included cost products sold see note addition common stock abbvie 's authorized capital includes million shares preferred stock par value december shares preferred stock issued outstanding form knote income taxes earnings income tax expense years ended december millions domestic foreign total earnings income tax expense income tax expense years ended december millions current domestic foreign total current taxes deferred domestic foreign total deferred taxes total income tax expense benefit effective tax rate reconciliation years ended december statutory tax rate effect foreign operations us tax credits impacts related us tax reform nondeductible expenses tax law changes related restructuring tax audits settlements net effective tax rate effective income tax rate fluctuates year year due allocation company 's taxable earnings among jurisdictions well certain discrete factors events year including changes tax law acquisitions collaborations effective income tax rates differed statutory tax rate principally due impact foreign operations reflects impact lower income tax rates locations outside united states tax incentives puerto rico foreign tax jurisdictions business development activities changes enacted tax rates laws related restructuring tax audits settlements changes fair value contingent consideration effective tax rates periods also reflected benefit us tax credits principally related research development credits orphan drug tax credit puerto rico excise tax credits puerto rico tax credits relate excise tax certain products manufactured puerto rico tax levied gross inventory purchases entities puerto rico included cost products sold consolidated statements earnings majority tax creditable us income tax purposes puerto rico enacted act puerto rico act allowing transition puerto rico excise tax levied gross inventory purchases incomebased tax beginning company completed transition requirements puerto rico act resulting remeasurement certain deferred tax assets liabilities based income tax rates expected reverse future net tax benefit remeasurement deferred taxes related puerto rico act million effective income tax rate included recognition net tax benefit billion related changes tax laws related restructuring including certain intragroup transfers intellectual property deferred tax remeasurement tax cuts jobs act act signed law december resulting significant changes us corporate tax system including one time transition tax mandatory deemed repatriation earnings certain foreign subsidiaries previously untaxed act also created minimum tax certain foreign sourced earnings companys accounting policy minimum tax foreign sourced earnings report tax effects basis minimum tax recognized tax expense year incurred period expense deferred tax assets liabilities december millions deferred tax assets compensation employee benefits accruals reserves chargebacks rebates advance payments net operating losses carryforwards total deferred tax assets valuation allowances total net deferred tax assets deferred tax liabilities excess book basis tax basis intangible assets excess book basis tax basis investments total deferred tax liabilities net deferred tax assets liabilities increase net deferred tax assets primarily related capitalization rd expense increases accruals reserves offset decrease advance payments decrease deferred tax liabilities primarily related amortization intangible assets connection allergan acquisition company recorded adjustments within measurement period related foreign net operating losses credit carryforwards expected realized adjustments reflected increase billion deferred tax assets offsetting increase valuation allowances resulting net impact deferred tax assets company valuation allowances billion december billion december principally related foreign state net operating losses credit carryforwards expected realized december company us federal state foreign credit carryforwards million well us federal state foreign net operating loss carryforwards billion expire various times remaining us federal foreign loss carryforwards billion expiration act significantly changed timing manner earnings foreign subsidiaries subject us tax therefore unremitted foreign earnings subject acts transition tax considered indefinitely reinvested post earnings subject us minimum tax foreign sourced earnings eligible percent foreign dividends received deduction also considered indefinitely reinvested earnings however company generally considers instances outside basis differences foreign subsidiaries would incur additional us tax upon reversal eg capital gain distribution permanent duration unrecognized tax liability practicable determine form kunrecognized tax benefits years ended december millions beginning balance increase due acquisition increase due current year tax positions increase due prior year tax positions decrease due prior year tax positions settlements lapse statutes limitations ending balance recognized net amount potential tax benefits would impact company 's effective tax rate billion billion increase due current year tax positions increase due prior year tax positions table include amounts related federal state international tax items increase due acquisition table includes amounts related federal state international tax items recorded acquisition accounting related allergan acquisition abbvie recognizes interest penalties related income tax matters income tax expense consolidated statements earnings abbvie recognized gross income tax expense million million million interest penalties related income tax matters abbvie accrual payment gross interest penalties billion december million december million december company routinely audited tax authorities significant jurisdictions number audits currently underway reasonably possible next months uncertain tax positions may settled could result decrease gross amount unrecognized tax benefits due potential resolution federal state foreign examinations expiration various statutes limitation company 's gross unrecognized tax benefits balance may change within next months million significant federal state local international matters concluded years company believes adequate provision made income tax uncertainties note legal proceedings contingencies abbvie subject contingencies various claims legal proceedings investigations regarding product liability intellectual property commercial securities matters arise normal course business significant matters described loss contingency provisions recorded probable losses managements best estimate loss best estimate made minimum loss contingency amount within probable range recorded litigation matters discussed loss probable reasonably possible company unable estimate possible loss range loss beyond amounts accrued initiation new legal proceedings change status existing proceedings may result change estimated loss accrued abbvie feasible predict outcome proceedings exposures certainty management believes ultimate disposition material adverse effect abbvies consolidated financial position results operations cash flows subject certain exceptions specified separation agreement abbott laboratories abbott abbvie abbvie assumed liability control pending threatened legal matters related business including liabilities claims legal proceedings related products part business discontinued prior distribution well assumed retained liabilities indemnify abbott liability arising resulting assumed legal matters antitrust litigation lawsuits pending abbvie others generally alleging patent litigation settlement involving niaspan entered kos pharmaceuticals inc company acquired abbott presently subsidiary abbvie generic company violates federal state antitrust laws state unfair deceptive trade practices unjust enrichment laws plaintiffs generally seek monetary damages andor injunctive relief attorneys ' fees lawsuits pending federal court consist four individual plaintiff lawsuits two consolidated purported class actions one brought niaspan direct purchasers one brought niaspan endpayors cases pending united states district court eastern district pennsylvania coordinated consolidated pretrial proceedings mdl rules niaspan antitrust litigation mdl august court certified class direct purchasers niaspan june august court denied endpayors ' motion certify class october orange county california district attorneys office filed lawsuit behalf state california regarding niaspan patent litigation settlement orange county superior court asserting claim unfair competition provision california business professions code seeking injunctive relief restitution civil penalties attorneys fees august direct purchasers androgel filed lawsuit king drug co florence inc et al v abbvie inc et al abbvie others united states district court eastern district pennsylvania alleging patent litigation settlements related agreements solvay pharmaceuticals inc company abbott acquired february known abbvie products llc three generic companies violated federal antitrust law also alleging patent litigation abbott two generic companies regarding androgel sham litigation settlements litigations violated federal antitrust law plaintiffs generally seek monetary damages andor injunctive relief attorneys fees november state oregon filed lawsuit multnomah county oregon circuit court making similar allegations regarding patent litigation one generic companies lawsuits pending forest laboratories llc abbvie subsidiary others generally alleging patent litigation settlements involving namenda entered forest generic companies conduct forest involving namenda violated state antitrust unfair deceptive trade practices unjust enrichment laws plaintiffs generally seek monetary damages andor injunctive relief attorneys fees lawsuits purported class actions filed indirect purchasers namenda consolidated namenda indirect purchaser antitrust litigation united states district court southern district new york november parties reached agreement settle matter received preliminary court approval lawsuits pending forest laboratories llc others generally alleging patent litigation settlements involving bystolic six generic manufacturers violated federal state antitrust laws state unfair deceptive trade practices unjust enrichment laws plaintiffs generally seek monetary damages andor injunctive relief attorneys fees lawsuits purported class actions filed behalf direct indirect purchasers bystolic consolidated bystolic antitrust litigation united states district court southern district new york government proceedings lawsuits pending allergan several manufacturers generally alleging improperly promoted sold prescription opioid products approximately matters pending allergan federal court cases consolidated pretrial purposes united states district court northern district ohio mdl rules national prescription opiate litigation mdl approximately matters pending various state courts plaintiffs cases include states counties cities municipal entities native american tribes union trust funds thirdparty payors private hospitals personal injury claimants generally seek compensatory punitive damages november allergan finalized terms settlement state local government entities native american tribes settlement subject certain conditions including allergan 's determination sufficient number government entities elect participate settlement abbvie recorded charge billion selling general administrative expense consolidated statement earnings second quarter related potential settlement shareholder securities litigation june lawsuit elliott associates lp et al v abbvie inc filed five investment funds abbvie cook county illinois circuit court alleging abbvie made misrepresentations omissions connection proposed transaction shire similar lawsuits filed july october abbvie instances chief executive officer court additional investment funds september illinois court granted abbvie 's motion summary judgment pending claims pending cases dismissing prejudice november illinois appellate court affirmed summary judgment abbvie 's favor december court denied plaintiffs ' petition rehearing october federal securities lawsuit holwill v abbvie inc et al filed united states district court northern district illinois abbvie chief executive officer former chief financial officer alleging reasons stated humira sales growth financial filings misleading omitted alleged misconduct connection humira patient reimbursement support services services items value allegedly induced humira prescriptions september court granted plaintiffs ' motion certify class may shareholder derivative lawsuit ranney v gonzalez et al filed delaware chancery court alleging form kcertain abbvie directors officers breached fiduciary duties based related allegations december abbvie directorofficer defendants filed motion dismiss plaintiff voluntarily dismissed lawsuit prejudice lawsuits pending allergan certain current former officers alleging made misrepresentations omissions regarding allergan 's textured breast implants lawsuits filed allergan shareholders consolidated united states district court southern district new york allergan plc securities litigation plaintiffs generally seek compensatory damages attorneys fees september court partially granted allergan 's motion dismiss september court granted plaintiffs ' motion certify class december court granted allergan 's motion summary judgment remaining claims dismissing prejudice plaintiffs appealing court 's motion dismiss summary judgment rulings april federal securities lawsuit nakata v abbvie inc filed united states district court northern district illinois abbvie certain officers alleging misstatements regarding potential effect safety information another companys product would food drug administrations approval labeling abbvies rinvoq may july two shareholder derivative lawsuits treppel family trust v gonzalez et al katcher v gonzalez et al filed court alleging certain abbvie directors officers breached fiduciary legal duties based related allegations product liability general litigation qui tam lawsuit us ex rel silbersher v allergan inc et al filed united states district court northern district california several allergan entities others alleging conduct us patent office resulted false claims payment made federal state healthcare payors namenda xr namzaric plaintiffrelator seeks damages attorneys ' fees federal false claims act state law analogues federal government state governments declined intervene lawsuit august united states court appeals reversed district courts denial allergans motion dismiss case remanded district court proceedings consistent ruling intellectual property litigation pharmacyclics llc wholly owned subsidiary abbvie seeking enforce patent rights relating ibrutinib tablets drug pharmacyclics sells trademark imbruvica cases filed united states district court district delaware march alvogen pine brook llc natco pharma ltd august court issued decision holding asserted patents infringed valid judgment precludes defendants obtaining regulatory approval launching last patent expires august defendants appealed november court appeals federal circuit affirmed judgment janssen biotech inc global collaboration pharmacyclics concerning development marketing imbruvica coplaintiff suits abbvie inc seeking enforce patent rights relating venetoclax drug sold trademark venclexta litigation filed united states district court district delaware july dr reddys laboratories ltd dr reddys laboratories inc alembic pharmaceuticals ltd alembic pharmaceuticals inc alembic global holdings sa abbvie alleges defendants proposed generic venetoclax products infringe certain patents seeks declaratory injunctive relief genentech inc global collaboration abbvie concerning development marketing venclexta coplaintiff suit note segment geographic area information abbvie operates single global business segment dedicated research development manufacturing commercialization sale innovative medicines therapies operating structure enables chief executive officer chief operating decision maker codm allocate resources assess business performance global basis order achieve established longterm strategic goals consistent structure global research development supply chain organization responsible discovery manufacturing supply products commercial efforts coordinate marketing sales distribution products organized geographic region therapeutic area activities supported global corporate administrative staff determination single business segment consistent consolidated financial information regularly reviewed codm purposes assessing performance allocating resources planning forecasting future periods substantially abbvie 's net revenues united states three wholesalers outside united states products sold primarily health care providers distributors depending market served following tables detail abbvie 's worldwide net revenues years ended december millions immunology humira united states international total skyrizi united states international total rinvoq united states international total hematologic oncology imbruvica united states collaboration revenues total venclexta united states international total aesthetics botox cosmetic united states international total juvederm collection united states international total aesthetics united states international total neuroscience botox therapeutic united states international total vraylar united states international total duodopa united states international total ubrelvy united states qulipta united states neuroscience united states international total form kyears ended december millions eye care lumiganganfort united states international total alphagancombigan united states international total restasis united states international total eye care united states international total key products mavyret united states international total creon united states linzessconstella united states international total total net revenues net revenues include allergan product revenues acquisition closing date may net revenues external customers geographic area based product shipment destination follows years ended december millions united states germany canada japan china france australia spain united kingdom italy brazil countries total net revenues longlived assets primarily net property equipment geographic area follows december millions united states puerto rico europe total longlived assets note fourth quarter financial results unaudited quarter ended december millions except per share data net revenues gross margin net earnings attributable abbvie inc basic earnings per share attributable abbvie inc diluted earnings per share attributable abbvie inc cash dividends declared per common share form kreport independent registered public accounting firm stockholders board directors abbvie inc opinion financial statements audited accompanying consolidated balance sheets abbvie inc subsidiaries company december related consolidated statements earnings comprehensive income equity cash flows three years period ended december related notes collectively referred financial statements opinion financial statements present fairly material respects financial position company december results operations cash flows three years period ended december conformity us generally accepted accounting principles also audited accordance standards public company accounting oversight board united states pcaob company 's internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework report dated february expressed unqualified opinion thereon basis opinion financial statements responsibility company 's management responsibility express opinion company 's financial statements based audits public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement whether due error fraud audits included performing procedures assess risks material misstatement financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation financial statements believe audits provide reasonable basis opinion critical audit matters critical audit matters communicated matters arising current period audit financial statements communicated required communicated audit committee relate accounts disclosures material financial statements involved especially challenging subjective complex judgments communication critical audit matters alter way opinion financial statements taken whole communicating critical audit matters providing separate opinions critical audit matters accounts disclosures relate sales rebate accruals medicaid medicare managed care programs description matter discussed note consolidated financial statements caption revenue recognition company established provisions sales rebates period related product sold december company million sales rebate accruals large portion rebates provided pharmacy benefit managers state government medicaid programs insurance companies administer medicare drug plans private entities medicaid medicare managed care programs order establish sales rebate accruals company estimated rebates based upon identification products subject rebate applicable price rebate terms estimated lag time sale payment rebate auditing medicaid medicare managed care sales rebate accruals complex required significant auditor judgment accruals consider multiple subjective complex estimates assumptions estimates assumptions included estimated inventory distribution channel impacts lag time sale customer payment rebate final payer related product sales impacts applicable price rebate terms deriving estimates assumptions company used internal external sources information estimate product distribution channels payer mix prescription volumes historical experience management supplemented historical data analysis qualitative adjustments based upon changes rebate trends rebate programs contract terms legislative changes significant events indicate change reserve appropriate addressed obtained understanding evaluated design tested operating effectiveness controls matter audit companys sales rebate accruals medicaid medicare managed care programs included testing controls managements review significant assumptions inputs used estimation medicaid medicare managed care rebates among others including significant assumptions discussed testing inclusive managements controls evaluate accuracy reserve judgments actual rebates paid rebate validation processing controls ensure data used evaluate support significant assumptions complete accurate applicable verified external data sources test sales rebate accruals medicaid medicare managed care programs audit procedures included among others understanding evaluating significant assumptions underlying data used managements calculations testing significant assumptions included corroboration external data sources evaluated reasonableness assumptions considering industry economic trends product profiles regulatory factors assessed historical accuracy managements estimates comparing actual activity previous estimates performed analytical procedures based internal external data sources evaluate completeness reserves medicaid involved specialist understanding statutory reimbursement requirements assess consistency companys calculation methodologies applicable government regulations policy form kvaluation contingent consideration description matter discussed note consolidated financial statements caption business combinations note caption fair value measures company recognized contingent consideration liabilities estimated fair value acquisition date connection applying acquisition method accounting business combinations subsequent changes fair value contingent consideration liabilities recorded within consolidated statement earnings period change december company million contingent consideration liabilities represented level fair value measurement fair value hierarchy due significant unobservable inputs used determining fair value use management judgment assumptions market participants would use pricing liabilities auditing valuation contingent consideration liabilities complex required significant auditor judgment due use monte carlo simulation model high degree subjectivity evaluating certain assumptions required estimate fair value contingent royalty payments particular fair value measurement sensitive significant assumptions underlying estimated amount future sales acquired products management utilized expertise within industry including commercial dynamics trends utilization well knowledge clinical development regulatory approval processes determine certain assumptions addressed obtained understanding evaluated design tested operating effectiveness controls matter audit companys contingent consideration liabilities process including among others managements process establish significant assumptions measure liability included testing controls managements review significant assumptions inputs used determination fair value testing inclusive key management review controls monitor evaluate clinical development acquired products estimated future sales controls ensure data used evaluate support significant assumptions complete accurate applicable verified external data sources test estimated fair value contingent consideration liabilities audit procedures included among others inspecting terms executed agreement assessing monte carlo simulation model used testing key contractual inputs significant assumptions discussed evaluated assumptions judgments considering observable industry economic trends standards external data sources regulatory factors estimated amounts future sales evaluated reasonableness relation internal external analyses clinical development progress timelines probability success benchmarks regulatory notices procedures included evaluating data sources used management determining assumptions necessary included evaluation available information either corroborated contradicted managements conclusions involved valuation specialist assess companys monte carlo simulation model perform corroborative fair value calculations ernst young llp served companys auditor since chicago illinois february item changes disagreements accountants accounting financial disclosure none item controls procedures disclosure controls procedures internal control financial reporting evaluation disclosure controls procedures chief executive officer richard gonzalez chief financial officer scott reents evaluated effectiveness abbvie 's disclosure controls procedures end period covered report concluded abbvie 's disclosure controls procedures effective ensure information abbvie required disclose reports files submits securities exchange commission securities exchange act recorded processed summarized reported within time periods specified commission 's rules forms ensure information required disclosed abbvie reports files submits securities exchange act accumulated communicated abbvie 's management including principal executive officer principal financial officer appropriate allow timely decisions regarding required disclosure changes internal control financial reporting changes abbvie 's internal control financial reporting defined rule af securities exchange act materially affected reasonably likely materially affect abbvie 's internal control financial reporting quarter ended december inherent limitations effectiveness controls abbvie 's management including chief executive officer chief financial officer expect abbvie 's disclosure controls internal control financial reporting prevent detect errors fraud control system matter well designed operated provide reasonable absolute assurance control system 's objectives met design control system must reflect fact resource constraints benefits controls must considered relative costs inherent limitations control systems evaluation controls provide absolute assurance misstatements due error fraud occur control issues instances fraud detected inherent limitations include realities judgments decisionmaking faulty breakdowns occur simple error mistake controls also circumvented individual acts persons collusion two people management override controls design system controls based part certain assumptions likelihood future events assurance design succeed achieving stated goals potential future conditions projections evaluation controls effectiveness future periods subject risks time controls may become inadequate changes conditions deterioration degree compliance policies procedures management 's annual report internal control financial reporting management abbvie responsible establishing maintaining adequate internal control financial reporting term defined rule af securities exchange act abbvie 's internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states however internal control systems matter well designed inherent limitations therefore even systems determined effective provide reasonable assurance respect financial statement preparation reporting management assessed effectiveness abbvie 's internal control financial reporting december making assessment management used criteria set forth committee sponsoring organizations treadway commission coso internal controlintegrated framework framework based assessment management concluded abbvie maintained effective internal control financial reporting december based coso criteria effectiveness abbvie 's internal control financial reporting december audited ernst young llp independent registered public accounting firm stated attestation report expresses unqualified opinion effectiveness abbvie 's internal control financial reporting december report independent registered public accounting firm report abbvie 's independent registered public accounting firm related assessment effectiveness internal control financial reporting included form kreport independent registered public accounting firm stockholders board directors abbvie inc opinion internal control financial reporting audited abbvie inc subsidiaries ' internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission framework coso criteria opinion abbvie inc subsidiaries company maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states pcaob consolidated balance sheets abbvie inc subsidiaries december related consolidated statements earnings comprehensive income equity cash flows three years period ended december related notes report dated february expressed unqualified opinion thereon basis opinion company 's management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's annual report internal control financial reporting responsibility express opinion company 's internal control financial reporting based audit public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audit accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion definition limitations internal control financial reporting company 's internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles company 's internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition company 's assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate ernst young llp chicago illinois february item b information none item c disclosure regarding foreign jurisdictions prevent inspections applicable form kpart iii item directors executive officers corporate governance incorporated herein reference information concerning director nominees board directors committeescommittees board directors communicating board directors deadlines notice stockholder actions considered annual meeting stockholders included abbvie inc proxy statement definitive proxy statement filed march also incorporated herein reference text found caption information executive officers abbvie 's code business conduct requires business activities conducted compliance applicable laws regulations ethical principles values directors officers employees abbvie required read understand abide requirements code business conduct applicable abbvie 's code business conduct available corporate governance section abbvie 's investor relations website wwwabbvieinvestorcom waiver code business conduct directors executive officers may made abbvie 's audit committee abbvie disclose amendment waiver provision code conduct principal executive officer principal financial officer principal accounting officer controller persons performing similar functions website within four business days following date amendment waiver addition abbvie disclose waiver code business conduct executive officers directors website abbvie chief ethics compliance officer reports executive vice president general counsel secretary public policy committee chief ethics compliance officer responsible overseeing administering monitoring abbvie 's compliance program item executive compensation material included abbvie inc proxy statement headings director compensation executive compensation compensation committee report incorporated herein reference definitive proxy statement filed march item security ownership certain beneficial owners management related stockholder matters equity compensation plan information following table presents information december abbvie 's equity compensation plans abbvie common stock authorized issuance number c securities number securities remaining issued upon b available exercise weighted future issuance equity outstanding average exercise price compensation plans excluding options outstanding options securities warrants warrants reflected plan category rights rights column equity compensation plans approved security holders equity compensation plans approved security holders total includes shares issuable abbvie 's incentive stock program pursuant awards granted abbott adjusted abbvie awards connection abbvie 's separation abbott weightedaverage exercise price include outstanding restricted stock units restricted stock awards performance shares exercise price excludes shares issuable upon exercise stock options pursuant rights granted stemcentrx equity incentive plan assumed abbvie upon consummation acquisition stemcentrx inc december options remained outstanding plan options weightedaverage exercise price awards granted plan b information concerning security ownership incorporated herein reference material heading securities ownershipsecurities ownership executive officers directors abbvie inc proxy statement definitive proxy statement filed march item certain relationships related transactions director independence material included abbvie inc proxy statement headings board directors committees corporate governance materials procedures approval related person transactions incorporated herein reference definitive proxy statement filed march item principal accounting fees services material included abbvie inc proxy statement headings audit fees nonaudit fees policy audit committee pre approval audit permissible nonaudit services independent registered public accounting firm incorporated herein reference definitive proxy statement filed march form kpart iv item